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The formation of unwanted clots leads to heart attack and stroke that result in a large 
number of mortalities and morbidities in developed countries, including Singapore. 
Currently available anticoagulant drugs have some drawbacks including their non-
specific actions. Therefore novel anticoagulants that target specific steps in the 
coagulation pathway are being sought. We have been searching for new 
anticoagulants from snake venoms. Here, we report the purification and 
characterization of a novel anticoagulant protein, exactin from the venom of 
Hemachatus haemachatus (African ringhals cobra). The protein was purified from the 
crude venom using gel filtration and reverse-phase high performance liquid 
chromatography. The molecular mass of the purified protein was determined to be 
6621.12 ± 0.22 Da. Based on its sequence similarity and cysteine positioning it can be 
concluded that exactin belongs to three-finger toxin family. A dissection approach on 
the coagulation cascade revealed the target of exactin as extrinsic activation complex 
(FVIIa/TF/FX). To better understand the molecular mechanism, we examined the 
effect of exactin on various assays in which each part of the complex was removed 
sequentially. Removal of TF did not affect the inhibitory potency of exactin (IC50 
value 102.70 ± 11.71 nM compared to 116.49 ± 3.28 nM for the complete complex). 
However, in the absence of phospholipids the inhibition dropped by >1000 folds. 
Exactin also poorly inhibited the amidolytic activities of FVIIa and FXa, suggesting it 
exerts its inhibitory potency towards the entire complex. Kinetic studies showed that 
exactin exhibits a mixed-type inhibition towards FX activation by FVIIa/TFPL, FVIIa 
in presence of PL and FVIIa/sTF. The affinity of the inhibitor towards the enzyme-
substrate complex (FVIIa/TFPL/FX, Ki’ 30.62 ± 7.73 nM) was 5-fold higher compared 
to the enzyme complex (FVIIa/TFPL, Ki 153.75 ± 17.96 nM) suggesting its preference 




slight decrease in Ki of 184.25 ± 6.13 nM. Thus, exactin appears to bind to the 
complete complex better than FVIIa/FX complex. The affinity of exactin was 
drastically reduced by >1000 fold for FX activation in the absence of phospholipids 
(Ki’, 295 ± 7.07 µM; Ki, 1250 ± 56.6 µM), suggesting its preference towards 
membrane-bound complex. Its poor ability to inhibit the hydrolysis of chromogenic 
substrate by these complexes suggests that exactin preferably inhibits the 
macromolecular substrate complex. To understand macromolecular specificities, we 
examined its effects on FIX activation by FVIIa/TFPL complex. Exactin preferably 
inhibits FX activation than FIX activation (IC50 29.66 ± 5.27 µM; Ki’, 38.66 ± 10.27 
µM; Ki, 128.6 ± 12.54 µM). Interestingly, exactin also inhibits, but not potently, FX 
activation by the intrinsic tenase complex (FIXa/FVIIIa)PL as well as a 
metalloproteinase, RVV-X non-competitively (IC50 4.05 ± 0.32 µM; Ki, 1.67 ± 0.35 
µM and IC50 6.1 ± 2.9 µM; Ki, 2.79 ± 0.29 µM, respectively). These results indicate 
that exactin may bind to FX, (as distinct exosites are recognized by these 
enzyme/enzyme-cofactor complexes) thereby preventing its  proteolytic cleavage. 
To understand its usefulness as the anticoagulant lead, we also studied its toxicity. 
Exactin showed weak neurotoxicity in mice. The ex vivo studies with chick biventer 
cervicis muscle preparations, suggested that it is a reversible, postsynaptic neurotoxin. 
Thus we conclude that exactin is a novel three-finger toxin with dual function; a 
potent and specific anticoagulant effect on the FX activation by the complete extrinsic 
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1. Hemostasis  
The maintenance of blood fluidity in circulation is pivotal for the survival of an 
organism. Hemostasis, a process designed to arrest bleeding from injured blood 
vessels is a tightly regulated process and involves interactions between plasma 
proteins (coagulations factors, physiological inhibitors and fibrinolytic proteins) and 
blood cells (platelets, endothelial cells and monocytes) (Mackie and Bull, 1989; 
Hopper and Bateman, 2005; Sere and Hackeng, 2003). The various steps that are 
involved in the final accomplishment of clot formation are described below in detail: 
1.1. Mechanism of Hemostasis 
1.1.1. Vasoconstriction 
The vascular lumen is lined by endothelium that provides a non-thrombogenic surface 
maintaining the proper blood flow. This is achieved through the production of various 
anti-thrombotic agents like prostacyclin (PGI2), NO, ADPase, thrombomodulin, TFPI, 
heparan sulphate and TPA. Prostacyclin, NO and ADPase act by inhibiting the platelet 
adhesion (Becker et al., 2000) whereas thrombomodulin (Dahlbӓck and Villoutrix, 
2005), TFPI (Girard et al., 1989), heparan sulphate (Fredenburgh et al., 2002) and tPA 
(Dobrovolsky and Titaeva, 2002) mediate their action through interaction with the 
coagulation proteins.  
Vasoconstriction functions as an effective way to reduce blood loss immediately after 
a vessel injury via neurogenic vasospasm, precapillary sphincter constriction, humoral 
vasospastic phenomena (Mason and Saba, 1978; Mason et al., 1977) as well as by the 
release of vasoconstrictor endothelins (Agapitov and Haynes, 2002). This is usually 
followed by action of pro-thrombotic factors leading to the formation of a stable 
hemostatic plug that prevent the oozing out of blood from the injured surface. The 
various pro-thrombotic factors involved in this process include expression of TF on 
the endothelial cell luminal surface, release of vWF from endothelial Wiebel-Palade 
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bodies resulting in the platelet adhesion to sub endothelial collagen followed by the 
action of thromboxane A2 and platelet activation factor which further leads to platelet 
activation, aggregation and plug formation, involvement of plasminogen activator 
inhibitor-1 in preventing fibrinolysis and expression of P-selectin, an adhesion 
molecule that helps binding of platelets to endothelial surface (Maria et al., 1986). 
1.1.2. Platelet plug formation 
Primary hemostasis starts with recruitment and activation of platelets to the site of 
vascular injury forming a platelet plug via stimulation by collagen, ADP, TxA2, 
epinephrine, serotonin and thrombin (Jackson et al., 2009; Wei et al., 2009) (Fig. 1.1). 
This multi-activation process culminates into a stable platelet rich thrombus. The 
initial capture of platelets to collagen is facilitated by the interaction between collagen 
bound vWF and GPIb/V/IX receptor complex under conditions of high shear as found 
in arterioles and arteries (Jennings, 2009; Lenting et al., 2010; Nuyttens, 2011). The 
platelet-collagen binding is stabilized by the interaction of two major receptors, α2β1 
and GPVI to collagen surfaces. Integrin, α2β1 is known for its role in platelet adhesion 
and anchoring, whereas GPVI is known for platelet activation (Clemetson and 
Clemetson, 2001; Nieswandt and Watson, 2003). The cumulative effect of the above 
mentioned platelet activators also leads to the activation of the receptor GPIIb/IIIa that 
mediates platelet adhesion, aggregation and finally stable thrombus formation via the 
interaction of the receptor to fibrinogen, bridging the platelet cells (Jennings, 2009). 
During the platelet activation, ADP is released from granules and exhibit profound 
effects like platelet recruitment to site of injury, change in platelet shape, platelet 
aggregation and release of TxA2. This release of TxA2 further enhances platelet 






















Figure 1.1: Platelet plug formation. Upon vascular rupture, circulating 
platelets are captured on the exposed collagen and vWF in the vessel 
wall leading to a monolayer of activated platelets. The activated platelets 
formed induce the secretion of ADP and TxA2 from the adherent 
platelets resulting in changes in platelet shape and enhancement of 
platelet activation. Like collagen, thrombin also activates platelets by 
cleaving PAR-1 and PAR-4 receptors. In the continuance, platelet 
contacts promote growth and stabilization of the platelet plug [Adapted 





Molecules like serotonin and epinephrine also play minor roles in platelet activation 
by recruiting the platelet cells to the injury site and promoting procoagulant activity 
via retention of fibrinogen and thrombospondin to cell surface (Stegner and 
Nieswandt, 2011). Like collagen, thrombin also play major role in platelet activation 
by the cleavage of protease-activated receptors, PAR-1 and PAR-4 at the N-termini. 
However, it is independent of endothelial rupture and vWF mediated activation (Furie 
and Furie, 2008). Thrombin assisted activation results in release of ADP, serotonin 
and TxA2 that also activates other platelets and by so enhances thrombus formation 
(Schmidlin and Bunnett, 2001; Brass, 2003). 
Activation of both platelets and coagulation factors are interconnected in that latter 
can bind to platelets either through glycoprotein receptors or through exposed 
phospholipids during platelet activation as seen with thrombin formation on exposed 
PS surface by collagen-GPVI interaction (Siljander et al., 2001; Bouchard et al., 2001; 
Monroe and Hoffman, 2002; Heemskerk et al., 2002). This interaction can also 
mediate the release of procoagulant membrane blebs into coagulation system 
(Heemskerk et al., 2002) which is also facilitated by enhanced intracellular Ca
2+
 via 
platelet activation by ADP, TxA2 and thrombin (Brass, 2003). Platelet secretions are 
known to promote procoagulant activity of activated platelets by contributing FV, 
FVIII and fibrinogen. Activated platelets also support the contact activation pathway 
(Offermanns, 2006; Caen and Wu, 2010). 
1.1.3. Role of coagulation factors 
The first account of blood clotting was given by Hippocrates, Aristotle, Celsius and 
Galen who associated blood coagulability to cooling. However, they did not explain 
the concept of hemostasis in relation to coagulation. In 1720, French surgeon Jean 
Louis-Petit associated hemostasis to blood coagulation which was further supported 
with observations about hemophilia by Friedrich Hopff in 1828 (Owen, 2001). The 
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discovery of various components of coagulation process then has led to the postulation 
of the classic theory of blood coagulation by Paul Merowitz in 1945. According to his 
theory, prothrombin was converted to thrombin by thromboplastin in presence of Ca
2+
. 
The thrombin formed finally converts fibrinogen to fibrin. The theory also explained 
the presence of components of coagulation in the circulating blood and the absence of 
clots in normal blood flow was due to a lack of wettable surface on blood vessels 
(Beck, 1977). Though a number of coagulation factors (vWF, FV, FVII, FVIII, FIX 
and FXI) were discovered since then, how these factors sequentially played to convert 
fibrinogen to fibrin was not clear.  
In 1964, two separate models: the Cascade model (Macfarlane, 1964) and Waterfall 
model (Davie and Ratnoff, 1964) were proposed to explain the step-by-step sequential 
activation of coagulation factors. Both these models, starting from surface contact to 
fibrin formation, segregated the coagulation factors into an intrinsic and extrinsic 
pathway which converges in FXa formation, ultimately leading to fibrin clot via 
thrombin cleavage of fibrinogen (Fig. 1.2). The cascade model also emphasized the 
importance of phospholipids like phoshatidylserine in coagulation (Zwaal, 1978). 
However, these models failed to highlight hemostasis in vivo accurately as it could not 
explain why haemophiliacs bleed due to deficiency of FVIII and FIX, though 
FVIIa/TF would be expected to bypass the role of FVIII and FIX. Similarly, people 
with FVII deficiency have high tendency of bleeding even when intrinsic pathway 
functions normally (Hoffman, 2003). Also the deficiency of FXII, prekallikrein and 
HMWK prolonged clotting time in vitro however, failed to affect coagulation in vivo 
(Hoffman, 2003). It was with the finding of FIX activation by FVIIa/TF (Osterud and 
























Figure 1.2: The cascade and waterfall hypothesis of blood coagulation. 
The intrinsic pathway of coagulation is initiated by exposure of the contact 
factors (FXII, prekallikrein, HMWK) to an appropriate surface with 
subsequent activation of factor XI by factor XIIa. The extrinsic pathway of 
coagulation is initiated by exposure of factor VIIa to TF. Both pathways 
merge at the formation of FXa, finally culminating into fibrin clot 




1993; Oliver et al., 1999; Baglia and Walsh, 1998), importance of FVIIa/TF in 
initiating clotting in vivo (Nemerson and Esnouf, 1973; Nemerson, 1992) and 
discovery of TFPI (Broze, 1992) that has led to a revised view of coagulation cascade. 
These observations have derived the conclusion that intrinsic and extrinsic pathways 
are interrelated in vivo rather than functioning independently. 
1.1.3.1. Modern view of coagulation cascade 
A cell-based model of blood coagulation has been proposed, where the cellular 
components provide a phospholipid substratum on which coagulation proteins can 
exhibit their activity (Monroe et al., 1996; Kjalke et al., 1998; Allen et al., 2000; 
Hoffman and Monroe, 2001) (Fig. 1.3). The coagulation cascade can be divided into 
three phases: initiation, amplification and propagation. 
1.1.3.1.1. Initiation  
Coagulation is initiated when flowing blood comes in contact with cell-exposed TF to 
produce minute amounts of thrombin. There are two pathways by which TF can 
initiate thrombus formation, via vascular TF and microparticle derived TF. However, 
their relative roles in vivo are unknown (Chou et al., 2004). TF, a membrane protein is 
constitutively expressed on fibroblasts and smooth muscle cells of vessel walls (Drake 
et al., 1989). However, its expression on monocytes and endothelial cells can be 
induced by chemical stimuli (Semeraro et al., 1983; Bevilacqua et al., 1984). In the 
absence of vascular injury TF is masked from FVIIa by endothelial surface to prevent 
unwanted clot formation (Morrissey et al., 1987), but coagulation is initiated as soon 
as the endothelium ruptures to expose TF to FVIIa. TF associated with microparticles 
in the circulating blood are derived from leukocytes, monocytes, endothelial cells, 
platelets and smooth muscle cells (Giesen et al., 1999; Chou et al., 2004; Morel et al., 




















Figure 1.3: Cell based model of coagulation. The recent cell based model of blood 
coagulation explains the role of both coagulation factors and cells for preventing the 
blood loss during vascular injury. The different phases involved are A) Initiation 
phase where the encrypted TF on the TF bearing cell gets activated upon vascular 
rupture and captures circulating FVII and activates it. The activated FVIIa/TF 
complex (extrinsic tenase complex) generates small amounts of FXa and FIXa. The 
FXa produced is used to generate thrombin in small amounts that plays a major role 
in the next phase. B) Amplification phase where the small amounts of thrombin 
generated during initiation performs multiple roles like activating platelets, FVIII, 
FV and FXI. The activated FXI inturn activates FIX. Activated FIX is also 
contributed from initiation phase. C) Propagation phase is characterized by the 
thrombin burst that occurs when FX is activated by intrinsic tenase complex 
(FIXa/FVIIIa). The activated FX complex with activated FV to form the 
prothrombinase complex (FXa/FVa) converting prothrombin to thrombin. The 
thrombin produced converts soluble fibrinogen to insoluble fibrin. It also helps to 
stabilize fibrin clot by activating FXIII. Fibrin clot is also stabilized by FXIIa 






They exist in an inactive form (lacks cofactor activity) in the blood stream due to yet 
to be confirmed reasons (Furie and Furie, 2008). It has been proposed that activated 
platelets and endothelial cells at the site of vascular injury expresses protein disulfide 
isomerise (PDI) that activates the inactive TF, thus helping in thrombus formation 
(Reinhardt et al., 2008; Cho et al., 2008).  During platelet activation at the site of 
vascular injury, P-selectin, a cell adhesion molecule gets expressed on the cell surface. 
This captures the circulating TF expressed microparticles via the receptor P-selectin 
glycoprotein ligand 1 (PSGL-1) and thus increases the local concentration of TF 
(Falati et al., 2003; Furie and Furie, 2004) leading to fibrin formation. However, this 
pathway may operate only in the presence of low concentration of vascular TF (Chou 
et al., 2004).  
During vascular injury, plasma FVII binds to TF exposed on cell surface and readily 
gets activated (Rao and Rapaport, 1988; Rao et al., 1996). Apart from the cofactor 
induced activation, FXa, FIXa and less predominantly, FVIIa present in the plasma 
can also activate FVII (Masys et al., 1982; Wildgoose and Kisiel, 1989; 
Neuenschwander et al., 1993). Recently, a novel protease has been characterized in 
the human plasma called as factor VII activating protease (FSAP) that can also 
activate FVII. However, it has been shown to activate pro-urokinase as well (Rӧmisch, 
2002; Kanse et al., 2008). FSAP circulates in plasma as an inactive zymogen and gets 
activated by auto-catalytic mechanism that is enhanced by heparin (Muhl et al., 2009). 
The FVIIa/TF complex also known as extrinsic tenase complex can activate both FX 
and FIX (Fujikawa et al., 1975; Osterud and Rapaport, 1977).The FIXa recruited to 
the platelet surface mediates the amplification phase (discussed below), while FXa 
generated on TF bearing cell can activate FV (Monokovic and Tracy, 1990) and 
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complex with it to form the prothrombinase complex (discussed under propagation 
phase). The prothrombinase complex can generate small amounts of thrombin which  
can subsequently activate FXI (Walsh, 2001; Matafonov et al., 2011) and FVIII 
during amplification phase (Monroe et al., 1996; Camire and Bos, 2009). 
1.1.3.1.2. Amplification  
The second phase in the coagulation cascade occurs on platelet surface (Hoffman and 
Monroe, 2001; Furie and Furie, 2008). Thrombin produced in the initiation phase 
activates both platelets (Hung et al., 1992; Schmidlin and Bunnett, 2001) as well as 
the coagulation factors FV, FVIII and FXI leading to a thrombin surge as discussed in 
propagation phase. Apart from plasma, FV is also found in alpha granules of platelets 
and is secreted on to the surface during platelet activation by thrombin. This FV is 
activated either by thrombin or FXa (Monokovic and Tracy, 1990; Camire et al., 
1998). Recent reports have shown that poly phosphates, a linearized polymer of 
inorganic phosphate released from platelets can also enhance FV activation (Smith et 
al., 2006). FVIII on the other hand is observed in plasma as an inactive complex with 
vWF. During initiation, through a proteolytic cleavage by thrombin, FVIII gets 
activated and detached from vWF. The activated FVIII is then recruited on to the 
platelet surface (Myles et al., 2002; Fay, 2006). FVIII is also shown to be activated by 
FIXa (Rick, 1982), FXIa (Whelihan et al., 2010), FXa (Saenko et al., 1999) and 
FVIIa/TF (Soeda et al., 2010), however their physiological significance is unknown. 
The current cell-based model of coagulation does not support FXI activation by FXIIa 
as seen with cascade/waterfall hypothesis (Macfarlane, 1964; Davie and Ratnoff, 
1964; Kravtsov et al., 2009). This is based on the observation that unlike FXIIa, FXIa 
deficiency causes bleeding in patients (Seligsohn, 2007; Gailani and Neff, 2009). Also 
FXII is not involved in hemostasis; however recent findings show its role in 
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thrombosis (Schousboe, 2008; Schmaier, 2008). Thus it is postulated that FXI is 
activated during haemostasis by proteases rather than by FXIIa. FXI is activated by α-
thrombin (Naito and Fujikawa, 1991; Gailani and Broze, 1991), meizothrombin 
(Matafonov et al., 2011) and through auto-activation (Naito and Fujikawa, 1991; 
Gailani and Broze, 1991) on platelet surface. The platelet surface is important for FXI 
activation as thrombin fails to activate circulating FXIa (Pedicord et al., 2007). The 
FXIa formed sustains thrombin generation through activation of FIX. Amplification 
phase there by prepares activated cofactors FV and FVIII for the next step where 
procoagulant complexes are assembled to produce a thrombin burst. 
1.1.3.1.3. Propagation 
A large number of platelets are recruited at the site of injury. The intrinsic tenase 
(FIXa/FVIIIa) and prothrombinase complex (FXa/FVa) are assembled on platelet 
surface (Hoffman and Monroe, 2001). The local concentration of FIXa is enhanced on 
the platelet surface by FXIa as well as from TF bearing cell, where it was produced 
during initiation (Mannhalter et al., 1984; Osterud and Rapaport, 1977). The intrinsic 
tenase activates FX which complexes with FVa to produce thrombin via cleavage of 
prothrombin (Mann et al., 2003). The formation of a stable hemostatic fibrin clot by 
thrombin marks the final step in blood coagulation. The fibrin clot formed from 
fibrinogen fills the injured site and prevents blood loss. Fibrinogen is a dimer of a 
trimer having two Aα, Bβ and γ chains linked by disulfide bonds. The -NH2 termini of 
all the chains are closer together at the centre constituting the E domain whereas –
COOH termini are present in the globular regions at the ends constituting D domain. 
Thrombin cleaves the Aα and Bβ chains without touching γ chains forming fibrin 
monomers comprising of two α, β and γ chains. These monomers polymerizes 
immediately forming fibrin protofibrils in a half-staggered overlap fashion which later 
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associate laterally and longitudinally to form a thick fibrin mesh. During clot 
formation, thrombin catalyzes the activation of FXIII. FXIIIa, a transglutaminase 
catalyzes the formation of intermolecular γ-glutamyl-ε -lysine crosslinks in the fibrin 
network there by stabilizing blood clot. Thrombin also helps in stabilizing the fibrin 
clot by activating TAFI (Bajzar et al., 1995). Apart from its role in isopeptide bond 
formation, FXIIIa can also cross-link a variety of other cell surface proteins and 
lipoproteins into the formed fibrin clot helping in wound healing and tissue repair 
(Nesheim, 2003; La Corte et al., 2011; Komaromi et al., 2011). Recent findings show 
that FXIIa mediates the regulation of fibrin structure, elasticity and susceptibility to 
lysis via binding to fibrin(ogen). Upon activation, FXII can yield α-FXIIa (with a 
heavy and light chain linked by disulfide bond) and β-FXIIa after further proteolysis 
(with light chain alone). The α-FXIIa can mediate the activation of FIX, finally 
resulting in fibrin formation via thrombin. α-FXIIa can directly bind to fibrinogen (site 
unknown) and results in a denser and stable fibrin clot (Konings et al., 2011). 
1.1.3.1.4. Fibrinolytic system 
Once a fibrin clot is formed over the site of injury, the clotting process must be 
restricted spatially to avoid thrombotic occlusion in adjacent normal areas of the 
vasculature. This is aided by a fibrinolytic system that can mediate clot dissolution 
once the wound gets healed. The system is composed of plasminogen, several 
activators and inhibitors. Plasmin, the key fibrinolytic enzyme is formed by the 
proteolytic activation of plasminogen. Fibrin has binding sites for both plasminogen 
and t-PA where proteolytic reaction occurs (Robbins et al., 1967; Castellino, 1984). t-
PA release at the site of injury from endothelial cells is stimulated by fibrin, thrombin 
and by blood vessel occlusion (Amery et al., 1962; Levin et al., 1984; Kaplan et al., 
1989). t-PA by itself is a poor activator of plasminogen until and unless it gets bound 
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to fibrin (Camiolo et al., 1971). u-PA also a plasminogen activator plays significant 
role in tissue degradation that facilitates cell migration during wound healing and 
tissue repair (Dano et al., 1985). FXIIa, FXIa and kallikrein can also activate 
plasminogen, however their physiological relevance is still under conformation 
(Colman et al., 1975; Mandle and Kaplan, 1979; Colman, 1969). Plasmin cleaves 
fibrin sequentially to release the degradation products. Lys/Arg residues on the α and 
β chains are prone for proteolysis (Dobrovolsky and Titaeva, 2002). The plasmin 
activity is regulated through the effect of α2-antiplasmin and α2-macroglobulin with 
α2-antiplasmin having a major role (Wiman and Collen, 1978; Aoki and Harpel, 
1984). AT, α1-antitrypsin and C1 inhibitor have also shown to inhibit plasmin in in 
vitro studies (Aoki and Harpel, 1984). Inhibitors regulating the activity of 
plasminogen activators involve PAI-1, PAI-2, PAI-3 and the protease nexin of which 
PA-1 has significant role in inhibiting t-PA (Baker et al., 1980; Chandler et al., 1990) 
and FVIIa/TF (Sen et al., 2011). Recently thrombin-activatable fibrinolysis inhibitor 
(TAFI) or plasma carboxypeptidase B has been characterized. TAFI is activated by T-
TM complex (Bajzar et al., 1995). TAFI removes the carboxy terminal end of fibrin 
there by making fibrin inaccessible for plasminogen activation via t-PA (Wang et al., 
1998). Activation of TAFI is controlled by APC (Bajzar et al., 1996). Recently, it was 
shown that poly phosphates can enhance the activity of TAFI there by delaying the 
clot lysis (Smith et al., 2006). 
1.2. Regulation of hemostasis 
Uncontrolled coagulation can lead to thromboembolic disorders after receiving a 
modest procoagulant stimulus (Hoffman, 2003). This explains the significance of an 





















Figure 1.4: Physiological regulation of hemostasis. Thrombin/ 
thrombomodulin complex plays a major role in activating TAFI and 
protein C. Activated protein C and TAFI regulates 
coagulation/fibrinolysis.  TFPI is the endothelial cell–associated 
inhibitor of tissue factor pathway where it inhibits both FXa and FVIIa 
to form a quaternary complex. Antithrombin binds to endothelial 
glycosaminoglycans, which causes a more efficient inhibition of 
activated coagulation proteases like FXa and thrombin. Release of 
plasminogen activators from endothelial cells will affect local 
fibrinolysis. Minus sign indicate inhibitory effects. [Adapted and 




1.2.1. Tissue factor pathway inhibitor 
TFPI is an endogenous serine protease inhibitor for the tissue factor pathway. A major 
proportion of TFPI (75-90 %) is localized in endothelial cells where as the remaining  
circulates bound to plasma lipoproteins (Gentry et al., 2008). Because of its 
association with lipoproteins, TFPI was formerly known as lipoprotein-associated 
coagulation inhibitor or LACI (Girard et al., 1989). TFPI is also found to be present in 
platelets at lower concentrations and is secreted out upon activation by thrombin 
during vascular injury (Novotny et al., 1988; Mast et al., 2000). TFPI, a single-chain 
32-kDa glycoprotein consisting of three multivalent Kunitz type domains (K1, K2 and 
K3) is characterized by an acidic N-terminus and a basic C-terminal tail (Broze, 
1992). It is a bi-directional inhibitor in that it inhibits both FXa and FVIIa/TF (Broze 
et al., 1990). The mechanism of inhibition is explained as follows (Fig. 1.5). TFPI 
with its K2 domain inhibits the active site of FXa to form a 1:1 complex. This is 
followed by the recruitment of K1 domain to the active site of FVIIa/TF forming a 
stable quaternary complex (Salemink et al., 1999). The function of the K3 domain 
however has remained an enigma, but is suggested to localize TFPI to cell surface. K3 
domain as well as basic C-terminal tail are also believed to interact with lipoproteins, 
glycosaminoglycans and heparins (Piro and Broze, 2004; Lwaleed and Bass, 2006) 
and are known to have a role in anticoagulation by TFPI (Nordfang et al., 1991; Wun, 
1992; Valentin et al., 1993; Enjyoji et al., 1995). During the TF mediated coagulation, 
TFPI functions as a feedback regulator of FVIIa/TF. The production of activated FIX 
and FX by FVIIa/TF makes TFPI to get manifested and prevents further generation of 
FIXa and FXa. The FXa formed can produce small amounts of thrombin that can 






















Figure 1.5: Tissue factor pathway inhibitor. The tissue factor 
pathway inhibitor (TFPI) is a three Kunitz domain (represented as K) 
endogenous inhibitor. It inhibits both FXa and FVIIa to form a 
quaternary complex. With its K2 domain, TFPI first binds to the 
active site of FXa and later recruits K1domain into the active site of 
FVIIa. However, the K3 domain and the C-terminal tail are suggested 
to interact with proteoglycans. 
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Further production of FXa is achieved through intrinsic tenase complex, when FIXa 
formed is recruited to the platelet surface (Broze, 1995; Kalafatis et al., 1997).  
1.2.2. Serine protease inhibitors (serpins)  
A number of serpins has been characterized that can regulate the hemostatic system 
(Silverman et al., 2001). This includes antithrombin (AT also known as antithrombin 
III/ATIII) along with its cofactor heparin inhibiting the activity of several coagulation 
proteases (FXa, FIXa, FXIa, FXIIa, thrombin, FVIIa, plasmin and kallikrein) (De 
Agostini et al., 1990; Gettins and Olson, 2009); Heparin cofactor II (HCII) 
specifically inhibiting thrombin via binding to thrombin exosite 1 with its acidic N-
terminal tail (Colwell et al., 1999; Tollefsen, 2004; O’Keeffe et al., 2004; Tollefsen, 
2007); α1-antitrypsin and α1-protease inhibitor inhibiting thrombin, FXIa, FXa, APC 
and plasmin (Scott et al., 1982; Long et al., 1984); α2-Macroglobulin inhibiting FXa 
(Fuchs and Pizzo, 1983); C1 inhibitor inhibiting FXIa, FXIIa and kallikrein (Harpel et 
al., 1985; Pixley et al., 1985); protein C inhibitor (PCI) also known as plasminogen 
activator inhibitor-3 inhibiting thrombin, FXa, FXIa, APC, tissue-type plasminogen 
activator and urokinase-type plasminogen activator (Meijers et al., 2002; Pike et al., 
2005). Though PCI inhibits APC in presence of heparin, it’s physiologically relevant 
role is in inhibiting the thrombin-thrombomodulin complex (Yang et al., 2003); 
protein Z-dependent protease inhibitor (ZPI), a cofactor dependent serpin inhibiting 
FXa and FIXa (Huang et al., 2011; Vasse, 2011); protease nexin-1 (PN-1) inhibiting 
thrombin in the presence or absence of heparin (Evans et al., 1991). It can also bind to 
TM and mediate the inhibition of thrombin catalytic activity as well as thrombin 





1.2.3. Protein C system  
The thrombin generation during the coagulation cascade is regulated via keeping a 
check on FVIIIa and FVa by protein C anticoagulant system as they are cofactors for 
intrinsic tenase and prothrombinase complex respectively. The system involves 
thrombin-thrombomodulin (T-TM) complex, protein C, protein S and endothelial cell 
protein C receptor (EPCR) (Esmon, 2001; Esmon, 2003). Protein C, a vitamin K-
dependent serine protease circulates as a zymogen in the plasma. It is composed of 
two chains: a heavy chain and light chain linked by disulfide bridges. The γ-
carboxyglutamic acid (Gla) residues in the light chain help protein C to interact with 
endothelial receptor EPCR, which is essential for its activation. The Gla residues also 
help the activated protein C (APC) to interact with negatively charged phospholipids 
during its inhibition of FVIIIa and FVa (Dahlbӓck and Villoutreix, 2005; Wildhagen 
et al., 2011). The T-TM-EPCR complex removes the activation peptide from protein 
C’s heavy chain there by converting the serine protease domain to an active 
conformation. APC is highly specific in inactivating FVa and FVIIIa. Both the 
cofactors share similar domain arrangement of A1–A2–A3–C1–C2, and gets activated 
upon removal of the carbohydrate rich B domain during cleavage by thrombin or FXa. 
Three APC cleavage sites have been identified with Arg306, Arg506, Arg679 on FVa 
and Arg336, Arg562, Arg740 on FVIIIa (Fay et al., 1991; Hockin et al., 1999). 
Cleavage at Arg506 results in partial loss of FVa activity compared to that of Arg306, 
upon cleavage of which results in severe loss of FVa activity. The total loss of activity 
is however accounted to the removal of A2 domain after cleavage at Arg306 (Mann et 
al., 1997). In the case of FVIIIa the inactivation by APC requires protein S and FV as 
cofactors (Shen and Dahlbӓck, 1994; Shen et al., 1997; Nicolaes and Dahlback, 
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2002). However, the molecular mechanism by which APC along with the two 
cofactors inactivate FVIIIa in the tenase complex is not understood completely.  
1.3. Thrombotic disorders 
Blood coagulation, a hemostatic response to vascular injuries is a highly synchronized 
and tightly regulated cascade that involves sequential activation of various blood 
coagulation factors ultimately leading to the formation of fibrin clot. Any imbalance 
in its regulation can lead to either excessive bleeding through a cut (hemorrhage) or 
unwanted clot inside a blood vessel (thrombosis) (Mann et al., 2003; Furie and Furie, 
2008). Thrombosis via vascular occlusion is the major cause of morbidity and 
mortality in western populations (Gross and Weitz, 2008; Streiff et al., 2011). 
Thrombosis can be classified into venous and arterial with venous thrombosis 
triggered by changes in coagulation factors and their inhibitors resulting in restricted 
blood flow. While arterial thrombosis is due to rupture of vascular endothelium and 
increased platelet activity. However, these are not mutually exclusive in that increased 
fibrinogen in the blood and platelet activity can be associated with arterial and venous 
thrombosis respectively. Sometimes the thrombus formed can break off from the site 
of formation into the circulatory system obstructing the blood flow and are often 
called as an embolus/moving clot (Phillips et al., 2001). This results in 
thromboembolic disorders characterized as deep venous thrombosis (DVT), 
pulmonary embolism (PE), myocardial infarction (MI) and stroke (Kuntz et al., 2006; 
Furie and Furie, 2008). It has been estimated that out of the 16.7 million deaths in 
2002, 7.2 and 5.5 million deaths were due to MI and stroke respectively, making them 
globally the lead killers (Anderson and Chu, 2007). On the other hand, PE and DVT 
together known as venous thromboembolism (VTE) has an incidence of 1-3 out of 
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every 1000 of the general population per year and constitutes the third most common 
cardiovascular disorder (Kearon, 2001; Naess et al., 2007).  
1.4. Antithrombotic agents 
Arterial (MI and stroke) and venous thrombotic (DVT and PE) disorders are the 
leading causes of debilitation and death all over the world. Thus there is the need for 
effective antithrombotic therapy for the prevention and treatment of these disorders. 
Over the years, many antiplatelets, anticoagulants and thrombolytics have been 
developed and commercialized. By analyzing the nature of thrombus formed, the 
antithrombotic therapy can be instituted. Incidence of arterial and venous thrombosis, 
mainly thrombus extension, recurrence and embolic complications can be treated 
using antiplatelets and anticoagulants respectively. However, these agents cannot 
dissolve the existing clot in the system for which thrombolytics are used (Sikka and 
Bindra, 2010). A list of antithrombotics, currently in clinical trials and therapy has 
been discussed: 
1.4.1. Antiplatelets 
The conversion of coronary-artery plaque from stable to unstable with the subsequent 
plaque rupture leads to acute coronary syndrome (ACS), ranging from unstable angina 
to acute myocardial infarction (AMI). This plaque rupture results in the exposure of 
the thrombogenic surface, leading to platelet plug formation and finally arterial 
thromboembolic disorders (Fitzgerald and Shipp, 1992). Currently used antiplatelet 
agents include aspirin, P2Y12 inhibitors (ticlopidine and clopidogrel) and 
glycoprotein IIb/IIIa inhibitors. Aspirin irreversibly acetylate cyclooxygenase-1 
thereby inhibiting arachidonate induced platelet activation and aggregation and 
greatly reduce TxA2 synthesis (Patrono et al., 2005). Aspirin considered as a gold-
standard in antiplatelet therapy due to its cost effectiveness and low risk factors, 
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however has exhibited many pitfalls. Aspirin has shown to be ineffective to many 
patients during treatment, especially in inhibiting TxA2 production (Moser and Bode, 
2010; Lopes, 2011). Strategies were devised for either inhibiting thromboxane 
synthetase or blocking thromboxane receptors (Gaussem et al., 2005). Targeting 
thromboxane synthetase (final step in synthesis of TxA2) has got limited efficacy, as 
its inhibition will result in endoperoxide precursors that can act as platelet agonists 
(Fitzgerald et al., 1988). These inhibitors can also be used in association with receptor 
antagonists to achieve maximum efficacy. However, these two strategies have not 
performed well in humans as compared to aspirin (Ghuysen et al., 2005). A 
thromboxane antagonist, S18886 was found to be orally active in preventing platelet 
aggregation and has been pushed for large phase II trials (Gaussem et al., 2005; Weitz 
et al., 2008). 
The P2Y12 receptor that mediates ADP-induced platelet activation and aggregation 
has been targeted for antiplatelet therapy (Kunapuli et al., 2003; Kim and Kunapuli, 
2011). Thioenopyridines like ticlopidine and clopidogrel were used as receptor 
antagonists (Becker et al., 2008; Cairns and Eikelboom, 2008; Mega et al., 2009).  
Human platelets express both PAR-1 and PAR-4 receptors which when activated by 
thrombin results in platelet activation and aggregation. However, affinity of thrombin 
for PAR-1 is higher than that for PAR-4. Even PAR-1 is activated with lower 
amounts of thrombin as compared to that of PAR-4 activation (Bahou, 2003). This 
has made PAR-1 a better target in antiplatelet therapy. The two PAR-1 antagonists 
undergoing phase II evaluation are SCH-530348 and E5555. Both these antagonists 
exhibited mild bleeding and better protection from adverse cardiovascular events 
when administered orally to healthy volunteers (Seiler and Bernatowicz, 2003; Weitz 
et al., 2008; Moser and Bode, 2010).  
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Platelet aggregation, independent of agonists like ADP and TxA2 are mediated 
through the interaction of GP IIb/IIIa receptor on adjacent platelets to a molecule of 
fibrinogen representing the final step in the formation of platelet-rich thrombi 
(Jennings, 2009). By preventing this interaction, platelet aggregation can be checked. 
The inhibitors falling in this category include eptifibatide, tirofiban, and abciximab 
with eptifibatide and tirofiban as competitive inhibitors and abciximab permanently 
blocking the receptor (Hirsh and Weitz, 1999; Van de Werf, 2009). cAMP promotes 
suppression of platelet activation and subsequent aggregation. Drugs like 
dipyridamole and cilostazol inhibits phosphodiesterase, thereby increasing the level of 
cAMP. Since the risk of bleeding is low in this category of antiplatelets, they have 
been extensively evaluated in human trials for their use in stroke (Gross and Weitz, 
2009).  
1.4.2. Anticoagulants 
Anticoagulants have been used for more than 70 years for the treatment of deadly 
blood clots (Fig. 1.6). It was estimated that approximately 0.7% of the western 
population receives the oral anticoagulation therapy with heparin and vitamin K 
antagonists as the mainstays. (Gustaffson et al., 2004). Both these anticoagulants are 
highly effective when administered at proper dosages and relatively safe when 
monitored efficiently. Thus they have become the cornerstones in anticoagulation 
therapy. However, their clinical use is limited due to number of factors. 
1.4.2.1. Heparin 
Unfractionated heparin (UFH) is a heterogeneous mixture of polysaccharide chains of 
varying molecular weight. Chemical or enzymatic cleavage of UFH yields heparin 
chains of low molecular weight and hence the name low molecular weight heparin 
/LMWH. The anticoagulant activity of UFH and LMWH is mediated through its 
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interaction with the physiological anticoagulant AT via a distinct pentasaccharide 
sequence (Cosmi and Palareti, 2011). Thus heparin via AT can inhibit multiple targets 
like FXa, FIXa, FXIa and thrombin (explained in the section 1.2.2). The use of UFH 
has been greatly withdrawn due to the complications it caused in patients (Laux et al., 
2009). UFH exhibit tighter binding to plasma proteins and cells as compared to 
LMWH, resulting in variable pharmacokinetics. In addition, UFH also induces a high 
risk of heparin-induced thrombocytopenia (HIT) when compared to LMWH. HIT is 
an immune response generated when heparin interacts with the platelet factor-4. This 
interaction can also neutralize the heparins anticoagulant activity (Warkentin et al., 
2008). Heparin therapy also requires intense coagulation monitoring and cases of 
osteoporosis has also been reported (Hawkins, 2004). 
1.4.2.2. Vitamin K antagonists  
Coumarin derivatives like warfarin are used as vitamin K antagonists (VKAs) that 
exhibit their anticoagulant activity by targeting the hepatic synthesis of vitamin K 
dependent coagulation factors (Haas and Schellong, 2007). They does so by 
interfering with cyclic inter-conversion of vitamin K and its 2, 3-epoxide. Vitamin K 
functions as a cofactor for the γ-carboxylation reaction of clotting factors in their N-
terminal glutamic acid residues. The γ-carboxyglutamic acid (Gla) residues help these 
proteins to bind to the phospholipid membranes and enhance coagulation (O’Reilly, 
1976; Vermeer, 1984; Furie et al., 1999; Hirsh et al., 2001). However, the 
anticoagulant response of warfarin is challenged by many factors. In addition to their 
anticoagulant effect, the vitamin K antagonists exert procoagulant effect as well since 






















Figure 1.6: Cornerstones of anticoagulation therapy. A) The 
history of anticoagulants used for the treatment of arterial and 
venous thromboembolic disorders. Heparin and warfarin were 
the mainstays of coagulation therapy for more than 70 years. 
However, they have been replaced recently by direct thrombin 
inhibitors and FXa inhibitors to overcome the disadvantages 
posed by heparin and warfarin. B) The various anticoagulants in 
clinical use (or trials) targeting the different stages in the 
coagulation cascade. Note that heparin and warfarin can target 
different coagulation proteases. Due to their limitations, 
inhibitors targeting directly the extrinsic tenase complex, FXa or 
thrombin have been sought [Fig. 1.6a is adapted from Ansell J. 




Warfarin’s use is limited due to its narrow therapeutic index. The anticoagulant 
response of warfarin is analysed by its effect on international normalized range (INR) 
that is derived from patient’s plasma prothrombin time. Maintaining the INR value of 
within the recommended therapeutic range requires frequent laboratory monitoring 
and appropriate dosage adjustments. Warfarin is known to be involved in drug and 
food interactions that affect its anticoagulant activity. Its drug interaction can cause an 
either a decrease or increase of anticoagulant activity. Certain herbal medicines are 
known to enhance warfarin effect thereby causing excessive bleeding. Warfarin’s 
effect is also limited by dietary consumption of vegetables rich in vitamin 
supplements. Apart from these, several disease states are also known to alter 
warfarin’s effects (Hirsh et al., 2001; Hawkins, 2004; Nutescu et al., 2006, Tsiara et 
al., 2011).  
1.4.2.3. FXa inhibitors 
FXa represents the common point in the coagulation cascade and inhibiting FXa can 
put a check on the thrombin burst. FXa inhibitors can be either direct (examples: 
rivaroxaban, apixaban etc.) or indirect (examples: fondaparinux and idraparinux). 
Rivaroxaban (Xarelto®; Bayer Schering Pharma) is a orally administered small-
molecule direct Factor Xa inhibitor that selectively and reversibly inhibits both free 
and clot-associated Factor Xa activity, as well as prothrombinase activity (Laux et al., 
2009). With its fast on-set of action, high oral bioavailability, fast clearance from the 
physiological system and low incidence of food and drug interactions, it has been 
approved for the treatment of VTE in several countries (Galanis et al., 2011). 
Otamixaban, a non-competitve inhibitor of FXa was subjected for phase IIa trials in 
patients with coronary artery disease and was found to exhibit sustained anti-FXa 
activity with no incidence of bleeding. It was also compared with heparin in phase II 
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trials where patients having PCI demonstrated reduction in Xa activity. Razaxaban, an 
oral FXa inhibitor underwent phase II trials for thromboprophylaxis after knee 
arthroplasty. However, it exhibited increased incidence of bleeding in patients given 
with higher doses and further development was stopped (Weitz et al., 2008). 
Apixaban, a variant of razaxaban exhibited greater bioavailability and 
pharmacokinetic properties. Like rivaroxaban, it is also a small molecule reversible 
inhibitor of FXa and prothrombinase activity. It is currently under phase III trials 
against VTE after orthopaedic surgery (Laux et al., 2009; Weitz, 2010). Other direct 
inhibitors of FXa include betrixaban and edoxaban, both of which are undergoing 
phase II trials (Harenberg and Wehling, 2011; Tsiara et al., 2011). Fondaparinux and 
idraparinux are indirect FXa inhibitors administered sub-cutaneously that mediate 
FXa inhibition through AT. Fondaparinux is a synthetic analogue of AT binding 
pentasaccharide found in heparin or LMWH where as idraparinux is a polymethylated 
derivative of the former (Harenberg, 2008). Fondaparinux is the most successful FXa 
inhibitor and has been approved recently for the treatment of thromboprophylaxis and 
VTE. The recent trials have confirmed its efficacy and safety in acute coronary 
syndrome. It does not induce HIT during treatment. Its high bioavailability, 
pharmacokinetic properties and non-requirement of timely coagulation monitoring 
make it advantageous (Haas and Schellong, 2007). Idraparinux on the other hand 
exhibits higher AT activity and a prolonged plasma half-life compared to 
fondaparinux (Alban, 2005; Kanagasabapathy et al., 2011).  It was highly efficacious 
in patients with DVT compared to that with patients having PE. Idraparinux was also 
associated with higher risk of bleeding though it was effective in preventing recurrent 
VTE. Idrabiotaparinux, a biotinylated version of idraparinux has subsequently been 
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developed that has a specific neutralizing agent. However, there were no further trials 
planned with either idraparinux or idrabiotaparinux (Levy et al., 2010). 
1.4.2.4. Direct thrombin inhibitors 
Thrombin plays a critical role in blood clotting in that it converts soluble fibrinogen to 
insoluble fibrin. It also exerts other thrombogenic properties like activating platelets, 
FXIII, FV, FXI and FVIII. Activated FXIII is required for fibrin clot stabilization. 
This explains the importance of thrombin as a target for anticoagulation therapy. 
Direct thrombin inhibitors (DTIs) inhibit thrombus formation and produce a more 
predictable anticoagulant effect. When compared to heparin, they neither bind to 
plasma proteins nor interact with platelet factor-4 (Harenberg, 2008). Some of these 
that are currently in the market are hirudin, bivalirudin, argatroban and dabigatran 
etexilate. Hirudin (Refludan®; Bayer HealthCare Pharmaceuticals) is a 65-residue 
protein isolated from the medicinal leech, Hirudo medicinalis. The recombinant 
hirudin is approved for the treatment in patients with HIT and for thromboprophylaxis 
after an orthopaedic surgery. However, its usage was limited due to risk of bleeding, 
lack of antidote, immunogenicity and pharmacokinetics that depend on renal function 
(Greinacher and Warkentin, 2008; Laux et al., 2009). Bivalirudin (Angiox®; The 
Medicines Company), a 20-residue peptide was designed based on hirudin structure. 
It was basically assigned for percutaneous coronary intervention (PCI). Compared to 
hirudin, bivalirudin was easily cleared off from the physiological system and 
exhibited negligible immunogenicity. It has been clinically accepted for both arterial 
and venous thrombotic disorders (Warkentin et al., 2008). Pegmusirudin, a chemically 
modified hirudin derivative prolongs the half-life of hirudin even in patients with 
renal disease. Like hirudin, pegmusirudin is cleared off via urinary system. Thus in 
phase II studies, it has been evaluated for its anticoagulant activity in patients with 
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end stage renal deficiency and as a strategy to reduce the risk of vascular graft 
occlusion (Avgerinos et al., 2001; Weitz et al., 2008). Argatroban (Argatra®; 
Mitsubishi Pharma), a small molecule inhibitor of thrombin has been approved for the 
treatment of patients with HIT (Yeh and Jang, 2006; Hirsh et al., 2008). Flovagatran, 
a synthetic small molecule reversibly inhibiting thrombin has been found to show 
predictable pharmacokinetics. Since its clearance from the system is via an extra-renal 
mechanism, it has been investigated in phase II trials as an alternative to heparin in 
patients undergoing hemodialysis with renal disease who have antibodies to 
heparin/platelet factor-4 complex (Weitz et al., 2008, Gomez-Outes et al., 2011). 
However, these DTIs were administered intravenous which have limited their long 
term use. This has led to the development of oral DTIs such as Ximelagatran 
(Exanta®; AstraZeneca) and dabigatran etexilate (Pradaxa®; Boehringer Ingelheim). 
Ximelagatran, a prodrug of thrombin inhibitor melagatran was evaluated for the 
treatment of VTE after orthopaedic surgery. It had undergone a phase III trial for 
stroke prevention in patients with atrial fibrillation. However, due to reports of 
hepatotoxicity and other adverse cardiovascular complications, Ximelagatran was 
withdrawn from further trials and development (Weitz et al., 2008). Dabigatran 
etexilate, the recently launched DTI in the market has been accepted by the European 
Commission for the treatment of VTE in patients who have undergone total hip or 
knee replacement surgery. Despite of its low bioavailability (5%), dabigatran etexilate 
does not require regular coagulation monitoring. The anticoagulant effect of 
dabigatran etexilate is associated with low bleeding risk without major problems of 
interactions with other drugs (Harenberg, 2008; Weitz et al., 2008; Gomez-Moreno et 





1.4.2.5. Extrinsic complex inhibitors 
Drugs that target extrinsic tenase complex (FVIIa/TF) prevent the initiation of 
coagulation and have reached the phase II and III trials. These include tifacogin, 
recombinant NAPc2 and active site inhibited FVIIa (factor VIIai). Tifacogin, a 
recombinant form of TFPI expressed in Saccharomyces cerevisae has been used in 
patients with sepsis and it is undergoing phase III trials. Initial clinical trials with 
NAPc2 on the other hand focused on venous thromboprophylaxis. In the phase II 
trials NAPc2 exhibited high efficacy and minimal bleeding when compared to 
historical anticoagulants. Currently, in phase II trials NAPc2’s role on arterial 
thrombosis is being evaluated. FVIIai function by competing with normal FVIIa in 
binding to TF and initiating coagulation. However, in human trials FVIIai exhibited 
poor performance towards arterial thrombosis and its further development was 
suspended (Weitz et al., 2008). PCI-27483 is a small molecule inhibitor of FVIIa/TF 
complex reported to exhibit antitumor and antithrombotic activities in preclinical 
trials. Currently, its phase Ib/II trials are carried out in patients with pancreatic cancer.  
1.4.2.6. Other new anticoagulants 
A human monoclonal antibody (TB-402) partially inhibiting FVIIIa was analyzed in 
phase II trials upon IV injection in patients with VTE undergoing total knee 
replacement surgery. TB-402 exhibited a high efficacy and reduced risk of bleeding at 
lower doses. Phase III trials are yet to be conducted with TB-402 (Gomez-Outes et 
al., 2011).  
Inhibitor targeting FIXa (RB006) has been developed as RNA aptamer, that when 
administered parenterally binds FIXa with high affinity. Phase I trials has shown a 
prolongation of plasma APTT where it exhibited a fast neutralization in presence of 
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complementary oligonucleotides. Currently, its role in cardiopulmonary bypass 
surgery has been studied. TTP889 is an orally administered FIXa inhibitor that failed 
to pass the phase II trials (Rusconi et al., 2002; Eriksson and Quinlan, 2006, Weitz et 
al., 2008). 
Drotrecogin alfa (activated), a recombinant APC has been initially licensed in 2001 to 
be used as a FVa inhibitor in patients with severe sepsis and high risk of death. It 
indeed reduced the mortality rate though incidence of high bleeding was reported. 
However, later clinical trials in patients with severe sepsis and low risk of death have 
proven it to have low efficacy and higher risk of bleeding, thus limiting its use 
(Bernard et al., 2001; Abraham et al., 2005; Boyle et al., 2011). ART-123, a 
recombinant analogue of TM can bind to thrombin there by activating protein C. 
During phase II trials in patients with hip arthroplasty, it showed high efficacy against 
VTE but associated with major bleeding. It also exhibited high bioavailability when 
administered subcutaneously (Kearson et al., 2005; Gomez-Outes et al., 2011).  
1.4.3. Fibrinolytics 
Although antiplatelets and anticoagulants are meant for preventing the recurrent 
incidence of thromboembolism, they have a negligible role in removing already 
formed clots in the arteries or veins. Clot removal is thus mediated through either 
indirect or direct fibrinolytic/thrombolytic agents. 
Indirect fibrinolytic agents are fibrinolysis enhancers. PAI-1 is the physiological 
inhibitor for t-PA that converts plasminogen to plasmin and thereby increasing the 
fibrinolysis. Lipid lowering drugs has been reported to reduce the expression of PAI-1 
along with other proteins which makes them non-ideal (Brown et al., 1995). Peptides 
and small molecules that can block PAI-1 activity have been devised; however they 
require in vivo studies (Eitzman et al., 1995; Friederich et al., 1997). Inhibitors 
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characterized from potato as well as small molecules were found to inhibit TAFI but 
were limited with the fact that low doses of the inhibitor enhanced TAFI activity 
(Nagashima et al., 2000; Schneider and Nesheim, 2003; Guimaraes et al., 2006). 
Inhibition of FXIIIa can destabilize the fibrin clot that can be prone to lysis later. 
FXIIIa inhibitors involve tridegin and destabilase enzyme from leech (Baskova and 
Nikonov, 1991; Seale et al., 1997; Finney et al., 1997). However, these inhibitors 
haven’t reached human trials. Recently, variants of t-PA have been licensed to be 
used as fibrinolytic agents. These include reteplase and tenecteplase (Noble et al., 
1996; Dunn and Goa, 2001; Llevadot et al., 2001). Desmoteplase is a plasminogen 
activator analogue from the vampire bat Desmodus rotundus. Like t-PA, desmoteplase 
binds to fibrin and activate plasminogen to plasmin leading to fibrin degradation 
(Stewart et al., 1998). Currently, it is under phase III trials with patients suffering 
from acute ischemic stroke though it has been reported to have exhibited low efficacy 
(Weitz et al., 2008).   
Direct fibrinolytic agents directly lyse the clot and include Alfimeprase. It is derived 
from fibrolase, a zinc-metalloprotease isolated from the venom of Agkistrodon 
contortrix contortrix. It directly degrades fibrin and fibrinogen. Since alfimeprase is 
inhibited physiologically by circulating α2-macroglobulin, it has to be administered 
directly to the thrombus site in order to prevent its systemic limitations. Clinical trials 
with alfimeprase have been carried out using catheter-directed lysis of peripheral 
arterial occlusions. Phase III trials have been suspended temporarily because of its 
inadequacy in meeting the standards (Moll et al., 2006; Weitz et al., 2008).  
1.5. Choice of the antithrombotic agent  
As the famous saying ‘Prevention is better than cure’, use of antiplatelets and 
anticoagulants are highly advantageous in treating thromboembolic disorders when 
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compared to fibrinolytics as the latter is used to dissolve the existing thombi. 
Antiplatelets are effective in initial and long term management of ACS as well as 
coronary, cerebral and peripheral artery disease (PAD) respectively. They do prevent 
thromboembolic events in atrial fibrillation (AF) and VTE but when compared to 
anticoagulants are less effective. On the contrary, anticoagulants are effective for 
initial and long term management of both arterial (ACS and stroke) and venous 
thrombotic disorders (DVT and PE). Though they exhibit high risks of bleeding; by 
optimizing dosage regimens and developing new anticoagulants, the bleeding 
problems can be counteracted (Eikelboom and Hirsch, 2007; Vedovati et al., 2010). 
Thus anticoagulants are pivotal for the prevention and treatment of thrombotic 
disorders. 
1.6. Ideal target for anticoagulation  
Traditional anticoagulants like warfarin and heparins have many pitfalls in that it 
targets many coagulation factors at a time, there by affecting the normal hemostasis. 
Strategy has been adopted to design new anticoagulants that can target a specific 
coagulation factor or step in the cascade without hindering hemostasis. Currently, 
anticoagulants are designed targeting FXa and thrombin. Thrombin represents the 
final stage in coagulation where it converts soluble fibrinogen to insoluble fibrin. It 
also helps in clot stabilization via activating FXIII and TAFI. It also has role in 
activating platelets along with FV, FXI and FVIII. Thus inhibiting the central role of 
thrombin can ensure proper anticoagulation, however can exhibit pleiotropic effects 
(Gurm and Bhatt, 2005; Bauer, 2006). FXa occupies a critical juncture in the 
coagulation cascade and is responsible for the thrombin burst. Thus a check on FXa 
can inhibit thrombin generation while allowing existing thrombin to continue its vital 
functions in normal hemostasis. FXa inhibitors also exhibit less bleeding compared to 
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DTIs (Bauer, 2006; Borensztajn et al., 2008; Borensztajn and Spek, 2011). It was 
hypothesized that selective inhibition of coagulation factors located further upstream 
(FVIIa/TF) in the cascade might be safer with respect to bleeding risk. Also, by not 
inhibiting thrombin activity directly can ensure a proper hemostasis. Furthermore, it 
was hypothesized that, as the amount of coagulation factors is amplified at each step 
of coagulation, targeting the upstream especially extrinsic tenase complex, might be 
more effective than those directly inhibiting FXa and thrombin. The critical nature of 
extrinsic tenase complex in initiating the coagulation process makes it an attractive 
target for anticoagulation therapy (Bates and Weitz, 2005; Mackman et al., 2007; 
Shirk and Vlasuk, 2007). The significance of FVIIa/TF in coagulation was further 
supported by the fact that recombinant FVIIa therapy provided normal hemostasis in 
patients with severe haemophilia in the absence of FIX and FVIII (Hedner and Ezban, 
2008; Hedner, 2008). Also exposure of TF during orthopaedic surgery and in certain 
patients with cancer may contribute to the high rates of VTE in these groups, making 
it an important target for anticoagulation therapy (Spyropoulos. 2007). FVIIa/TF is 
also known to be involved in cancer metastasis (Mueller et al., 1992), tumor 
angiogenesis (Zhang et al., 1994) and sepsis (Taylor et al., 1991). FIXa is also an 
attractive target for anticoagulants as most of FXa is produced by the intrinsic tenase 
complex. However, targeting the extrinsic tenase complex can put a check on both 
FXa and FIXa generation as both of them are the physiological macromolecular 
substrates for the tenase complex.  
1.7. Extrinsic tenase complex 
The extrinsic tenase complex or the initiation complex is comprised of FVIIa with its 
physiological cofactor; membrane bound TF that converts the macromolecular 
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substrates FX and FIX to their active forms. A detailed account of the structure and 
function of the tenase complex with respect to FX has been discussed. 
1.7.1. Tissue factor 
TF also known as factor III or thromboplastin or CD142 (Type II cytokine receptor) is 
a 263-residue transmembrane glycoprotein, consisting of an extracellular domain (1-
219), a transmembrane domain (220-242) and a cytoplasmic tail (243-263) (Morrissey 
et al., 1987; Spicer et al., 1987). TF is abundantly found on fibroblasts, advential 
pericytes and medial smooth muscles of vessel wall. It is also profusely found on 
many non-vascular cells, monocytes and endothelial cells. However, their presence on 
granulocytes and platelets requires further clarification. They are also present in 
circulating blood as microparticles derived from leukocytes, monocytes, platelets, 
endothelial cells and smooth muscle cells (Daubie et al., 2007; Furie and Furie, 2008). 
In addition to initiating coagulation, TF is also involved in intracellular signalling 
associated with angiogenesis, metastasis and maintenance of yolk-sac vasculature 
(Carmeliet et al., 1996; Belting et al., 2004; Dorfleutner et al., 2004). The 
extracellular part of TF consists of two compact fibronectin type III (FNIII) domains 
each folded into a  β-sandwich containing a four-stranded and a three-stranded 
antiparallel sheet. These two domains, called TF1 (residues 1-107) and TF2 (residues 
108-219), are connected by a polypeptide linker and the angle between the two is 
approximately 125º. The interface between the domains is extensive, with a large 
hydrophobic core, which is likely to be rigid, thus making TF a firm template for 
FVIIa binding (Harlos et al. 1994, Muller et al. 1994, Muller et al. 1996). TF has four 







) and one at the cytoplasmic tail (Asn
261
), however their functional role in 
cofactor activity is not known as recombinantly expressed TF also expresses full 
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activity (Paborsky et al., 1989; Paborsky and Harris, 1990). Though there were many 
reports regarding the influence of glycosylation on TF procoagulant activity (Egorina 
et al., 2008), it was shown recently that glycosylation does not have any effect on TF 
in terms of its transportation as well as procoagulant activity (Kothari et al., 2011), 
thus validating the findings of Paborsky et al. The cytoplasmic tail is modified by 
phosphorylation of several serine residues as well as palmitoylation of cys
245
.  The 
phosphorylation plays an important role in upregulation of procoagulant activity and 
PAR-2 mediated cell signalling whereas palmitoylation regulates phophorylation of 
TF cytoplasmic tail as well as targeting TF towards lipid rafts, there by modulating 
TF procoagulant activity (Egorina et al., 2008). It has been postulated that TF is 
expressed as an encrypted form on the membrane surface that lacks coagulant 




 present between 
the two FNIII domains provides structural stability where as the C-terminal allosteric 




 also links the C-
terminal FNIII to transmembrane domain there by stabilizing TF on the cellular 
membrane. There are contradictory views related to TF procoagulant activity 
regulated by PDI. According to one view that supports the role of PDI, oxidation of 
free thiols in the encrypted/inactive form of TF to form the disulfide linkage can 
conformationally activate TF such that it can bind to FVIIa and initiate coagulation 
(Chen et al., 2006; Chen and Hogg, 2006). Activated platelets and endothelial cells at 
the site of vascular injury release PDI that can mediate in decryption of TF (Cho et 
al., 2008; Reinhardt et al., 2008). The other view proposed by Pendurthi et al., 
challenged the existing hypothesis of PDI mediated TF decryption (Pendurthi et al., 
2007). According to them, surface exposed phosphatidylserine rather than PDI is 
responsible for the activation of encrypted TF (Kunzelmann-Marche et al., 2000; 
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Pendurthi et al., 2007). This was supported by the recent finding that PDI enhances 
TF activity via its chaperone activity and independent of oxidoreductase activity 
(Versteeg and Ruf, 2007). Contrastingly, the chaperone effect of PDI in activating FX 
by FVIIa/TF was disapproved (Persson, 2008). Apart from these theories, 
experimental evidences have shown various other means by which TF can be 
decrypted, via calcium ionophores, exposure to stimuli like cell lysis, apoptotic 
signals and TF self-association and association with specialized membrane domains 
(Greeno et al., 1996; Popescu et al., 2010). It is still uncertain about the exact 
mechanism by which TF procoagulant activity is regulated in vivo. 
1.7.2. Factor VII/VIIa 
Factor VII (FVII) is a 50 kDa vitamin K dependent serine protease synthesized in the 
liver. It circulates as a zymogen at a plasma concentration of 10 nM (Kalafatis et al., 





of FVII mediated through α-thrombin and FXa (Radcliffe and Nemerson, 1975), FIXa 
(Seligsohn et al., 1979), FVIIa (Lawson et al., 1992) and FXIIa (Kisiel et al., 1977). 
The active form of the enzyme has a light chain (152 residues) and a heavy chain (254 
residues) linked by a disulfide bond. The light chain is composed of an N-terminal 
membrane binding γ-carboxyglutamic acid – rich (Gla) domain and two epidermal 
growth factor (EGF) domains while the heavy chain constitutes the protease domain. 
The overall structure of Gla-domainless free FVIIa (Pike et al., 1999; Kemball-Cook 
et al., 1999) resembled to that in complex with TF with the protease domain 
associated with the light chain to form an extended and compact structure (Banner et 
al., 1996). This structural arrangement resembles to that of other coagulation 
proteases like FXa (Padmanabhan et al., 1993), FIXa (Brandstetter et al., 1995) and 
APC (Mather et al., 1996). The EGF-1 domain is rotated by 180º around the EGF-
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1/EGF-2 linker, compared to TF/FVIIa complex. The two EGF modules are linked 
closer to each other via a hydrogen bond to provide an extended conformation and 
exhibit identical conformations in the free and complex structure. Compared to the 
complex structure, the N-terminal of EGF-1 has a partially formed and unoccupied 
Ca
2+ 
binding site which could be inferred to the absence of Gla domain in the free 
FVIIa structure.  
The active site inhibitor used in the structure of Pike et al. was same as that used by 
Banner et al. However, there was difference in the binding, indicating conformation 
changes in the protease domain upon interaction with cofactor TF. The protease 





) flanking the active site cleft when compared to FVIIa/TF. In FVIIa/TF, this 
region has a α-helix (307-312) followed by a loop. The N-terminal part of the helix 
and Met
306
 preceding the helix form the TF interface. In free FVIIa this helix is 
distorted. This could be explained by the absence of an N-capping Asp or Glu residue 
at 306 position that provides a helical conformation as seen in other serine proteases 
like FXa, thrombin and trypsin. However, in FVIIa this position is occupied by a 
conserved Met residue. When FVIIa binds to TF, this Met
306
 gets sandwitched in a 









, links the 
helix to the activation domain thereby stabilizing it. This explains how TF enhances 




 region is 
also affected by the glycosylated Asn
322
 that follows the α-helix (307-312). However, 
this N-glycosylation is not attributed to proteolytic activity and TF binding but 
suggested to play a role in substrate recognition. The active site inhibitor imposed an 
active conformation for free FVIIa on the protease domain that includes proper 
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insertion of N-terminal Ile
153
 deep into the protease domain. This inturn facilitates the 
formation of S1 recognition pocket and oxyanion hole. The N-terminal Ile
153
 gets 
stabilized when it forms a salt bridge with Asp
343
. These changes are also induced in 
FVIIa when it binds to TF (Pike et al., 1999; Persson, 2000).  
The FVII zymogen structure comprising of EGF-2 and protease domain was solved in 
the presence of an exosite inhibitor A-183 (Eigenbrot et al., 2001). Comparing this 
structure with that of FVIIa/sTF (Banner et al., 1996) and FVIIai (Pike et al., 1999), it 
was concluded that significant differences were found mostly with the second β barrel 
that contains the activation domain. These include the absence of a calcium binding 
site and substrate binding cleft. However, differences in the first β barrel were 
attributed to the binding of A-183. The N-terminus in the activation domain was 
found to be linked to EGF-2. Major changes were also observed with the TF binding 
region of the protease domain, which was due to the alteration in the β-strand B2 
(Eigenbrot, 2002).  
1.7.3. TF/FVIIa: an allosteric pair 
The crucial role of FVIIa/TF complex in initiating the blood coagulation has led to the 
detailed characterization of the complex. The TF/FVIIa complex exemplifies a perfect 
allosteric pair (Fig. 1.7). The light chain of FVIIa constitutes the region with high 
allosteric influence. This is through the interaction of eight Ca
2+
 to the Gla and EGF-1 
domain of FVIIa. The FVIIa protease domain exhibits three allosteric sites: the TF 
binding region, the active site binding cleft and the macromolecular substrate binding  
exosite.  The macromolecular substrate exosite is located between the calcium binding 
site and the N-terminal insertion region and mainly composed of acidic residues 
(Dickinson et al., 1996; Ruf and Dickinson, 1998). These three allosteric sites are 
organized such a way that binding at any one these brings conformational changes to 
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the other two (Dickinson et al., 1998). TF binding to FVIIa can enhance both 
amidolytic (cleavage of small peptidyl substrates) and proteolytic (cleavage of 
macromolecular protein substrates) activities. This can be explained with the fact that 
FVIIa bound to membrane TF can enhance the catalytic activity to 10
5
 folds while the 
removal of phospholipids can only enhance the catalytic activity to just 50 folds. 
These can be well explained through the complex structure (FVIIa/sTF) solved at 2 Å 
(Banner et al., 1996). The structure shows a fully extended conformation of FVIIa 
over TF. A characteristic feature of Gla domain was the presence of seven bound Ca
2+ 
of which the linear row of six Ca
2+
 interacts with Gla6 and Gla7 to form a ‘W’ like 







down towards the cell membrane and it is speculated that this may help in the 
insertion of these residues to the phospholipid membrane. By doing so, the row of six 
calcium ions can be aligned along the phospholipid head groups. The Gla domain 
interacts with TF2 via hydrophobic interaction. The EGF-1 domain also harbours a 
calcium ion and it interacts with the interface of TF1/TF2. EGF-1 and EGF-2 are 
connected through a helix. The EGF-2 and catalytic domain are disulfide bonded and 




also called as 
methionine loop lies between TF binding region on the protease domain and substrate 
binding cleft. In the absence of TF, this loop might overlay on the active site or 
interact with Ile153 so that it cannot get inserted into the protease domain and later 
make salt bridge with Asp343. It was also suggested that Gla and EGF might also 
occlude the active site in the absence of TF. The active site in the protease domain of 




























Figure 1.7: TF/FVIIa: an allosteric pair. A) The structure of active site 
inhibited FVIIa/TF (the covalent inhibitor bound to the active site is 
represented in dark blue). FVIIa with its protease domain and light chain 
forms an extended and compact structure with its cofactor TF. There are 9 
Ca
2+
 bound (represented in green), 7 in the Gla domain, 1 in the EGF-1 
domain and 1 in the protease domain.  The Gla domain forms a ‘w’ like 
structure upon binding of the Ca
2+
 to Gla 6 and Gla 7 residues. This is 
considered to be important for interacting with the phospholipid membrane. 
The EGF-1 interacts with the interface of the two fibronectin domains of TF. 
The EGF-2 and protease domain are disulfide bridged and interacts with the 
fibronectin domain 1 of TF. B) Structure of the FVIIa protease domain 
showing regions of allosteric control. These include the TF binding region, 
substrate binding cleft and the macromolecular substrate exosite. The 
macromolecular substrate exosite is located between the calcium binding site 
(green sphere) and the N-terminal insertion region. Apart from these three 
sites, two new allosteric sites have been located on the protease domain. 
These are A- and E-site present in the first β-barrel. The ‘methionine loop’ is 
found between the TF binding region on the FVIIa protease domain and 
substrate binding cleft [Adapted from Eigenbrot, Current Protein and Peptide 
Science, 2002, 3, 287-299]. 
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FRET studies with free FVIIa and FVIIa/TF have shown that the active site was 
positioned 83 Å and 75 Å respectively from the membrane surface. In both the cases, 
FVIIa was oriented perpendicular to the membrane surface. This orientation of the 
active site with respect to TF binding could be attributed to the proper alignment of 
active site to the scissile bond of the macromolecular substrate (Morrissey, 2001). 
Recently, two exosites named as A-site and E-site was located in the first β-barrel 
domain of FVIIa protease domain (Eigenbrot, 2002). 
1.7.4. FX/Xa 
FX constitutes the macromolecular substrate for FVIIa/TF. Human FX is a vitamin K 
dependent glycoprotein (MW: 59 kDa) synthesized in the liver (Hertzberg, 1994). The 
circulating FX is activated by both extrinsic tenase (FVIIa/TF) and intrinsic tenase 
(FIXa/FVIIIa) on the membrane surface during which an activation peptide of 51 
residues is removed (Fujikawa et al., 1975; Panteleev et al., 2004). The FX/FXa is 
composed of a light chain (139 residues) and a heavy chain (303 residues) linked by a 
disulfide linkage. The N-terminal Gla domain has eleven Gla residues and can be 




 via chymotrypsin cleavage (Morita and 
Jackson, 1986). The Gla domain is followed by two EGF domains. These domains 
help FX to interact and align with FVIIa/TF and helps in its proteolysis (Ruf et al., 
1992; Kirchhofer et al., 2000). Mutational studies have shown that EGF-2 interacts 
with FVIIIa/FVa, the interaction which can also be enhanced by EGF-1(Skogen et al., 
1984; Hertzberg et al., 1992). The N-terminal EGF domain harbours a calcium ion 
thereby mediating the proper folding of Gla domain as isolated Gla domain have 
shown to exhibit minimal calcium binding (Persson et al., 1989; Persson et al., 1991). 
However the recently solved structure of FX binding protein (X-bp) with Gla 1-44 of 
FX showed the presence of seven calcium ions bound to the Gla residues. An eighth 
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calcium binding site formed by Gla35 and Gla39 was also observed in the C-terminal 
helix of Gla domain. These conserved residues are found only in FX and FIX and are 
suggested to interact with FVIIIa during intrinsic tenase complex formation (Mizuno 
et al., 2001). The protease domain of FXa, like other serine proteases (FVIIa, FIXa 
and trypsin) harbours a calcium ion binding site (Padmanabhan et al., 1993; 
Brandstetter et al., 1996). It also possesses a sodium ion binding site, the first of the 
monovalent binding site to be identified in FXa (Orthner and Kosow, 1980; Zhang 
and Tulinsky, 1997). The heparin binding or pro-heparin binding exosite on FXa/FX 
protease domain has also been characterized. This exosite not only facilitates binding 
of inhibitors like Ixolaris and NAPc2, but also help in recognizing FVa and 
prothrombin in the prothrombinase complex (Rezaie, 2000; Monteiro et al., 2008; 
Murakami et al., 2007).  
1.7.5. Assembly of extrinsic activation complex (FVIIa/TFPL/FX) 
The proper alignment of the macromolecular substrate, FX to the FVIIa/TF complex 
on the membrane surface initiates the activation process. FVIIa can complex with 
membrane bound TF via interactions that involve both light chain and heavy chain. 
The Ca
2+
 bound Gla domain helps FVIIa and FX to anchor on to the lipid membrane 
(Nelsestuen et al., 1978; Burnier et al., 1981).  The cell membrane is assumed to have 
been occupied by a large number of lipid micro domains rich in phospholipids 
(Lagerholm et al., 2005) and the Ca
2+
 influences the size and distribution of 
phospholipid micro domains on the surface (Haverstick and Glacer, 1987; Boettcher 
et al., 2011). It has been hypothesised that the lipid membrane with exposed 
phosphatidylserine (PS) and phosphatidylethanolamine (PE) plays an important role 
in holding the coagulations factors on to the surface (Tavoosi et al., 2011). PE by 
itself is a poor enhancer of clotting, but in presence of PS can augment the catalysis 
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by FVIIa/TF. The major portion of the cell membrane is composed of 
phosphatidylcholine (PC) and sphingomylein. PS and PE are usually confined to the 
inner leaflets of the membrane. Upon cell rupture and activation, these PS and PE get 
exposed on to the membrane surface (Neuenschwander et al., 1995; Zwaal et al., 
2005). Based on the lipid nanodisc studies with varying concentrations of PS, it has 
been concluded that the catalytic activity of FVIIa/TF has been enhanced several folds 
when compared to that incorporated in liposomes. Even FX incorporation on to the 
nanodisc has been found to increase with increase in PS%. Thus it can be inferred that 
PS function as a hot spot for the extrinsic activation complex on the membrane 
surface (Morrissey et al., 2011; Tavoosi et al., 2011). Using computer simulation 
studies and solid state NMR experiments with FVIIa Gla domain and nanodiscs, it has 
been shown that, Ca
2+
 not only stabilizes the Gla domain folding but also helps the 
Gla residues to interact with the phosphate groups of PS. The study also explained the 
insertion of Gla domain deep into the membrane surface such that Ca
2+
 can align 
properly with the phosphate moiety (Morrissey et al., 2010). The crystal structure of 
FVIIa/sTF also clearly shows the Ca
2+
 induced ‘W’ structure of Gla domain and 
protrusion of three hydrophobic residues that are believed to get inserted into the 
membrane (Banner et al., 1996). Using mutational studies, it has been found that 
multiple contact sites are involved in the enzyme complex for macromolecular 
substrate recognition and proteolysis apart from the enzyme’s catalytic cleft. Starting 
from the Gla domain of FVIIa, Arg
36
 is found to be important for bringing the Gla 
domain of FX closer to the complex on the membrane surface, site-directed 
mutagenesis of which has caused an increase in KM and a decreased Kcat. 
Computational studies have shown that FVIIa Arg
36
 interacts with FX Gla-14 




. These TF basic residues are in the close 
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proximity of FVIIa Gla Arg36 (Ruf et al., 1992; Huang et al., 1996; Ruf et al., 1999; 
Kirchhofer et al., 2000). The Ca
2+ 
binding site in EGF-1 of FVIIa and FX helps in 
stabilizing the structural orientation Gla domain with respect to EGF-1 domain. 




 in the calcium binding pocket of EGF-1 
resulted in reduced TF binding affinity which could be explained by the alteration in 
FVIIa light chain conformation. The changes either on EGF-1 or Gla domain can 
indirectly affect FX docking and proteolysis (Kelly et al., 1997; Jin et al., 1999). The 
EGF-1 of FVIIa also harbours functional residues important for its interaction with TF 
(Dickinson et al., 1996). Mutational studies has shown that EGF-1 of FX interact with 
TF which is prerequisite for its activation by the extrinsic tenase complex (Zhong et 
al., 2002; Thiec et al., 2003). However, in the protease domain of FVIIa the residues 
important for FX activation were positioned in three regions: specificity determinants 
in the substrate binding cleft, TF binding site and a macromolecular substrate exosite 
(Dickinson et al., 1996). During proteolytic activation of FX to FXα, an activation 




in the protease domain by 
FVIIa/TF. FXα is then converted to FXβ autoproteolytically by the hydrolysis of a 




) in the carboxyl terminal region of the 
protease domain. Both FXα and FXβ exhibited similar catalytic activity (Fujikawa et 
al., 1975; Pryzdial and Kessler, 1996) (Fig. 1.8). 
Apart from the activation by extrinsic tenase complex, FX is also proteolyticaly 
activated to FXa by the intrinsic tenase complex (FIXa/FVIIIa) (Panteleev et al., 
2004) and a FX activator from snake venom (Russel’s viper venom FX activator) 





1.7.6. Inhibitors targeting extrinsic activation complex: 
Over the years a number of inhibitors targeting the extrinsic complex (FVIIa/TF/FX) 
have been characterized. An overview of these inhibitors, specifically inhibiting the 
proteolysis of FX by FVIIa/TF has been discussed here: 
1.7.6.1. Monoclonal antibodies  
Monoclonal antibodies (mAbs) targeting the assembly of extrinsic complex can 
prevent the activation of FX and have potentials in antithrombotic therapy. They can 
be categorized into (I) mAbs that interfere with substrate binding to TF and (II) mAbs 
that prevent FVIIa binding to TF. In the first type that affects TF-FX association, 
mAbs are developed based on TF sequences primarily TF2 that interacts with Gla 
domain of FX (Fiore et al., 1992; Huang et al., 1998; Kirchhofer et al., 2000; Peng et 
al., 2007). The second type of mAbs is based on FVIIa-TF interaction sites mainly 
FVIIa light chain-TF and FVIIa methionine loop-TF (Carson et al., 1985; Pawashe et 
al., 1994; Kirchhofer et al., 2000).   
1.7.6.2. Peptides 
A cyclic pentapeptide (Cys-Glu-Gln- Tyr-Cys) based on the loop 1 of EGF-2 domain 
of FVIIa was found to inhibit TF dependent FX activation. It was a non-competitive 
inhibitor for FX without having any effect on FXa and FVIIa amidolytic activity 
(Örning et al., 2002). Similarly, peptide synthesized based on TF157-167 that 
corresponds to the TF2 region interacting with FX Gla domain was found to inhibit 
FX proteolysis (Rønning et al., 1996; Örning et al., 1998). Peptide based on FX Gla 
























Figure 1.8: Assembly of extrinsic activation complex 
(FVIIa/TF/FX). The FVIIa/TF constitutes the extrinsic tenase 
complex that catalytically activates the macromolecular substrate 
FX to form FXa. This occurs via the cleavage at Arg152-Ile153 
bond in the protease domain of FX, to release an activation peptide 
(AP) of 52 residues. Both the enzyme (FVIIa) and substrate (FX) 
have similar structure having a light chain and a heavy shain. The 
light chain is composed of Gla domain (G), EGF-1 (E1) and EGF-2 
(E2) domains. Both FVIIa and FX bind to the phospholipid 
membrane via their Gla domains. The heavy chain consists of the 
serine protease (SP) domain. Mutational studies have determined 
residues involved in the interaction of FX with FVIIa/TF. This 
interaction is essential for the proper alignment of the substrate 
along the FVIIa/TF in order to enable an efficient catalysis. The 
interaction site is mainly located in the Gla domain and EGF-1 of 
FX (discussed in the section 1.7.5] 
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1.7.6.3. Tissue factor pathway inhibitor (TFPI) 
Discussed in section 1.2.1 
1.7.6.4. Nematode Inhibitors 
Nematode anticoagulants characterized from Ancyclostoma species are thought to 
facilitate blood feeding in hookworms by preventing thrombosis. Nematode 
anticoagulant protein c2 (NAPc2) from A. caninum is an 8 kDa peptide that contains 
two antiparallel β-sheets and a short helix (Cappello et al., 1995; Duggan et al., 
1999). Both the natural and recombinant NAPc2 inhibited FVIIa/TF/FX via a unique 
mechanism resulting in the formation of a quaternary complex (Fig. 1.9).  It requires 
initial binding to FX/FXa at an exosite and later binding to FVIIa/TF active site, thus 
preventing the complete proteolysis of the substrate. Though the inhibition is similar 
to the physiological inhibitor TFPI, it differs in that TFPI binds to FXa active site. 
However, NAPc2 binding to exosite moderately affect the amidolytic activity of FXa 
(Bergum et al., 2001; Vlasuk and Rote, 2002; Lee and Vlasuk, 2003). The recently 
solved crystal structure of FXa-NAPc2 reveals the interaction of the peptide to a 
novel exosite overlapping with the heparin binding exosite of FXa. NAPc2 is thought 
to inhibit FVIIa active site via a P1 Arg residue present in its reactive loop (Murakami 
et al., 2007). Other nematode anticoagulants characterized from A. caninum are 
NAPc3 and NAPc4, both exhibiting similar inhibitory mechanism to NAPc2 
(Mieszczanek et al., 2004).  
1.7.6.5. Tick Inhibitors 
The well characterized tick inhibitors from the hard tick, Ixodes scapularis are Ixolaris 
and Penthalaris. Ixolaris is a two-Kunitz domain inhibitor whereas Penthalaris is a 
five-Kunitz domain inhibitor. Ixolaris exhibit inhibition similar to NAPc2 and TFPI 
but differ from the latter that like NAPc2 it binds to an exosite on FX/FXa and does 
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not affect the active site of FXa (Fig. 1.10). It is postulated that Ixolaris with its 
second Kunitz domain binds to FX/FXa exosite (proheparin/heparin binding exosite)  
followed by the docking of its first Kunitz domain of FVIIa/TF active site resulting in 
a quaternary complex. However in Ixolaris the P1 residue in the reactive site is Glu 
instead of a basic residue as seen in NAPc2 (Francischetti et al., 2002; Monteiro et al., 
2005; Monteiro et al., 2008). Penthalaris also exhibit a similar inhibitory mechanism 








































Figure 1.9: Mechanism of action of NAPc2. The nematode 
anticoagulant NAPc2 from Ancyclostoma caninum inhibits the FX 
activation by FVIIa/TF. It does by binding initially to a 
proexosite/exosite (proheparin/heparin binding exosite) on FX/Xa. 
This binary structure then interacts with the active site of FVIIa/TF 
forming a quaternary inhibited complex. It differs from TFPI in 
that it does not bind to FXa active site, however partially affects 





















Figure 1.10: Mechanism of action of ixolaris. Ixolaris is a two 
Kunitz domain inhibitor isolated from the hard tick, Ixodes 
scapularis. It exhibits a similar mechanism to NAPc2 in inhibiting 
the extrinsic complex. With its second Kunitz domain (K2), it 
forms a binary complex with FX/FXa by binding to an exosite 
(proheparin/heparin binding exosite). This mediates it to bind to the 
active site of FVIIa/TF via its first Kunitz domain (K1), leading to 
the formation of a quaternary inhibited complex. However 
compared to NAPc2, it enhances the amidolytic activity of FXa. 
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1.7.6.6. Snake venom inhibitors 
Snake venoms are composed of pharmacologically important peptides and proteins. 
They are used for paralyzing and digesting the prey (Russell, 1980; Harvey, 1991). 
Snake venoms can be neurotoxic (Brutto and Brutto, 2011) or hemotoxic (Sajevic, 
2011) depending upon their physiological action. Toxins that perturb the hemostatic 
system of the prey organism can be either procoagulant (Kini et al., 2001; Isbister, 
2009) or anticoagulant (Kini, 2006; Yamazaki and Morita, 2007, Kini, 2011). Since 
the current thesis deals with a snake venom protein inhibiting FX activation by 
extrinsic tenase complex, an over view of snake venom proteins targeting the extrinsic 
complex has been discussed here: 
1.7.6.6.1. Anticoagulant Phospholipiase A2 enzymes 
Phospholipase A2 (PLA2) is 13 kDa proteins that specifically cleave 
glycerophospholipids at the sn-2 position of the glycerol backbone releasing 
lysophospholipids and fatty acids. They have a typical fold, having a core of three α-
helices, a distinctive calcium loop and a β-wing that consist a single loop of 
antiparallel β-sheet around the calcium loop. In viperid and crotalids, the COOH-
terminal segment of PLA2 forms a semi-circular banister, around the Ca
2+ 
binding 
loop (Arni and Ward, 1996; Kini, 1997). PLA2s mediate their anticoagulation effect 
by the hydrolysis of phospholipids or by binding to them (Boffa and Boffa, 1976; 
Stefansson et al., 1990; Mounier et al., 2000). PLA2s can be categorized to non-
anticoagulant, weak and strong based on the concentration at which they can impose 
their anticoagulant effect (Boffa and Boffa, 1976). Weak anticoagulant PLA2s 
targeting the extrinsic tenase complex include superbins I and II or CM-I and CM-II 
from Austrelaps supererbus and Naja nigicollis respectively (Stefansson et al., 1989; 
Subburaju and Kini, 1997). The anticoagulant properties of CM-I and CM-II 
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depended on the presence of phospholipids (Stefansson et al., 1989). The PLA2 from 
B. lanceolatus was shown to inhibit FX activation by extrinsic tenase via a 
phospholipid-dependent manner (Lobo de Araujo et al., 2001). However, CM-IV 
strongly inhibited the extrinsic tenase complex via both enzymatic and non-enzymatic 
mechanisms (Kini and Evans, 1995). Based on the amino acid sequence analysis of 
strong, weak and non-anticoagulant PLA2s as well as chemical modification and site 
directed mutagenesis studies; an anticoagulant region has been proposed. In strongly 
anticoagulant PLA2s, the region that lies between residues 54 and 77 is positively 
charged and has a pair of lysine residues at both ends which is absent in both weak 
and non-anticoagulant PLA2s (Kini and Evans, 1987; Inada et al., 1994; Mounier et 
al., 2000) (Fig. 1.11A). 
1.7.6.6.2. Anticoagulant C-type lectin-related proteins 
C-type lectin-related proteins are structurally homologous with true C-type lectins 
but lack carbohydrate binding property (Ebner et al., 2003). FX binding protein (X-
bp) has been characterized from Deinagkistrodon acutus (Cox, 1993; Atoda et al., 
1998) and A. acutus (Xu et al., 2000) venoms. However, FIX/FX-binding proteins are 
characterized from T. flavoviridis (Atoda and Morita, 1989; Atoda et al., 1991), B. 
jararaca (Sekiya et al., 1993), Echis carinatus leucogaster (Chen and Tsai, 1996), 
and A. halys brevicaudus (Koo et al., 2002) snake venoms. A characteristic feature of 
these proteins is that they are αβ-heterodimers with a single disulfide linkage. Each 
subunit of these molecules consists of an extended loop that contributes to a tight 
interface with the other subunit via domain swapping. The dimeric interface 
contributes for a concave, binding site for coagulation factor Gla domain (Mizuno et 
al., 1999). The structure of FIX/FX-bp (Mizuno et al., 1997) and X-bp complexed 
with Gla domain of FX (Mizuno et al., 2001) has been solved. Ca
2+
 was found to be 
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essential for the activity as replacement with terbium hinders interaction with Gla 
domain of FX. These proteins prevent FX assembly on membrane surface by tightly 
binding to its Gla domain with a stoichiometry of 1:1 thereby preventing its activation 
(Fig. 1.11B).   
1.7.6.6.3. Anticoagulant three-finger toxins 
Three-finger toxins (3FTxs) belong to a family of non-enzymatic polypeptides 
containing 60-74 amino acid residues. Found in elapids, hydrophids and later in 
colubrids, 3FTxs are structurally characterized in having four or five disulphide 
bridges, of which four are conserved in all the members. Members of this family 
exhibit a similar pattern of protein folding: three β-stranded loops extending from a 
central core containing the four conserved disulphide bridges. Due to their structural 
appearance, they are commonly called as three-finger toxins. Inspite of having a 
common structural mould, they differ very much functionally, making them an 
interesting target for pharmacological studies (Tsetlin, 1999; Kini, 2002; Kini, 2006). 
Very little information is known about anticoagulant 3FTxs. The anticoagulant and 
antiplatelets effects of 3FTxs were first studied in cardiotoxins from Naja nigricollis 
crawshawii, however their mechanism of anticoagulation is not well understood (Kini 
et al., 1988). Recently, from our lab a novel anticoagulant 3FTx hemextin specifically 
inhibiting FVIIa was characterized (Fig. 1.11C). A heterotetramer, the two subunits 
hemextin A and B synergistically exhibited a non-competitive inhibition towards 
FVIIa with a Ki of 25 nM. An interesting feature about this inhibitor is that hemextin 
A itself is a mild anticoagulant whereas hemextin B did not show any activity. 
However, together they exhibited potent anticoagulation (Banerjee et al., 2005; 























Figure 1.11: Snake venom anticoagulant proteins. A) The ribbon model 
of the anticoagulant PLA2 from N. naja. The fully exposed and easily 
accessible predicted anticoagulant region is highlighted in red. Tryptophan 
regions are shown in yellow [Adapted from Kini, Biochem. J. (2006) 397, 
377–387]. B) The complex structure of X-bp with X-Gla domain (1-44 
residues). The X-bp, a heterodimer isolated from Deinagkistrodon acutus 
have two subunits represented in magenta and green. The bound Ca
2+
 on 
Gla domain (1-44 residues) is represented as blue spheres [Adapted from 
Mizuno et al., PNAS (2001) 98, 7230-7234]. C) The overall crystal 
structure of hemextin A, a novel anticoagulant 3FTx from H. haemachatus 
showing the β-strands. The disulfide linkages are shown in yellow 








1.8. Aim and Scope of the thesis 
Unwanted blood clots lead to heart attack and stroke that kill a large number of people 
in developed countries including Singapore. Current anticoagulation therapy has some 
drawbacks due to their non-specific actions. Therefore, pharmaceutical industries are 
searching for new drugs that specifically block individual clotting proteins. Snake 
venoms are complex mixtures of protein toxins that bind to particular human proteins 
and influence their biological effects. They can distinguish closely related protein 
receptors, ion channels and blood clotting proteins and hence have potential medical 
applications. Over the years toxins have provided impetus for the design and 
development of numerous therapeutic agents useful in the treatment of human 
diseases.  For example, Captopril (for lowering blood pressure) and Integrillin (for 
reducing unwanted clot formation in heart attack and stroke patients) were developed 
based on snake toxins. Previously, from our lab we have characterized snake venom 
3FTxs targeting two different stages of blood coagulation (hemextin targeting FVIIa 
and naniproin targeting the prothrombinase complex). This has given us the urge to 
search for novel anticoagulants especially targeting the extrinsic activation complex. 
Here we report a novel anticoagulant protein exactin from the venom of Hemachatus 
haemachatus that specifically inhibits FX activation by the extrinsic tenase complex 
without affecting FVIIa and FXa amidolytic activities, signifying its unique 
mechanism when compared to TFPI, NAPc2 and Ixolaris. To understand its 
usefulness as the anticoagulant lead, we also studied its in vivo toxicity and was found 
to be a weak reversible, post-synaptic neurotoxin in in vivo and ex vivo animal studies. 





Specifically the objectives were: 
1. To isolate and purify exactin from H. haemachatus crude venom. 
2. To structurally characterize exactin, in terms of its complete amino acid 
sequence and secondary structure determination. 
3. To understand the mechanism and kinetics by which exactin specifically 
inhibits FX activation by the extrinsic tenase complex. 
4. To evaluate the toxicity of exactin through in vivo and ex vivo animal studies. 
5. To identify the condition(s) for crystallizing exactin in order to solve its three-
dimension structure. 
On the whole the above mentioned objectives were all covered within the 
scope of this thesis. Objectives 1, 2 and 3 have been explained in detail in the 













































Protein and peptides accounts for 90-95 % of the dry weight of the crude snake 
venom. Size-exclusion chromatography (SEC) can be used as an initial step for 
purifying proteins from the crude venom. This separation technique based on 
molecular size can segregate proteins of various masses present in the crude venom 
like enzymes (>40 kDa), phospholipases (12-15 kDa), 3FTxs and serine protease 
inhibitors (6-8 kDa). SEC can be followed by reverse-phase high performance liquid 
chromatography (RP-HPLC) where proteins will be separated on the basis of 
hydrophobicity. As a final step in purification, RP-HPLC can yield purified proteins 
by optimizing parameters like choice of the column, ion-pairing agent, mobile-phase 
and slope of the eluting gradient. The mass and homogeneity of purified protein can 
be determined by electrospray ionization-mass spectrometry (ESI-MS).  
With the interest in developing the treatment for thromboembolic disorders, the search 
for novel anticoagulants, particularly three-finger toxins targeting the extrinsic 
complex, is carried out. Due to their small size, stable fold, non-enzymatic nature and 
insufficient exploration in anticoagulation studies, 3FTxs have become an exciting 
target. For the current study, Hemachatus haemachatus crude venom was selected. 
Though the venom contain both neurotoxic and cytotoxic components (Strydom and 
Botes, 1971; Fryklund and Eaker, 1973; Bengis and Noble, 1976), anticoagulant 
property for the first time has been attributed to a novel synergistically acting 3FTx, 
hemextin that mediate its effect through binding to an exosite on FVIIa (Banerjee et 
al., 2005, Banerjee et al., 2007). This has led us to screen for anticoagulants 
specifically targeting the extrinsic activation complex (FVIIa/TFPL/FX). The 
mechanism of action of the purified anticoagulant protein, exactin is determined using 
both clot-based and chromogenic assays (Pratt and Monroe, 1992; Walenga and 
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Hoppensteadt, 2005). A ‘Dissection Approach’ is carried out to delineate the target of 
exactin on the blood coagulation cascade (Fig. 2.1). It utilizes three clotting times: 
prothrombin time, Stypven time and thrombin time. “It is based on the simple 
principle that initiating the cascade upstream from the inhibited step will result in 
elevated clotting times, while initiating the cascade downstream from the inhibited 
step will not affect the clotting time” (Kini and Banerjee, 2005). The effect of an 
anticoagulant on extrinsic tenase (FVIIa/TFPL), prothrombinase complex (FXa/FVa) 
and the fibrin formation can be evaluated through prothrombin time while Stypven 
time circumvents extrinsic tenase complex, measures its effect on prothrombinase 
complex and fibrin formation. Thrombin time monitors its effect on fibrinogen 
conversion to fibrin. Chromogenic assays however, are based on enzyme specific 
peptidyl substrates on to which a chromophore has been linked. When the enzyme 
cleaves the substrate, it releases a chromophore which can be measured at a particular 
wavelength using a spectrophotometer.  
Overall this chapter deals with the purification and structural characterization of 
exactin along with the mechanism by which it specifically inhibits FX activation by 

















































Figure 2.1: Dissection approach. The sequential use of the 
three clotting times – prothrombin, Stypven and thrombin time 
can assign the anticoagulant site of an inhibitor in the 
coagulation cascade. Prothrombin time involves the initiation 
of clotting by the addition of thromboplastin (lipidated TF) with 
Ca
2+
. Stypven time involves the activation of plasma FX by a 
snake venom FX activator, RVV-X. Activated FXa along with 
FVa can complex to form prothrombinase complex and in 
presence of Ca
2+
 can convert prothrombin to thrombin. 
Thrombin time on the other hand measures the conversion of 
fibrinogen to fibrin by thrombin. 
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2.2. Materials and Methods 
2.2.1. Materials 
Lyophilized H. haemachatus crude venom was purchased from South African Venom 
Suppliers (Louis Trichardt, South Africa). Reagents for thromboplastin time, 
thrombin time and activated partial thromboplastin time (APTT) were from Helena 
Laboratories (Texas, USA). Reagents for N-terminal sequencing were from Applied 
Biosystems (California, USA). Acetonitrile was from Merck KGa (Darmstadt, 
Germany). Triflouroacetic acid and 4-vinylpyridine were from Sigma-Aldrich 
(Missouri, USA). β-Mercaptoethanol was from Nacalai Tesque (Kyoto, Japan). The 
chromogenic substrates, S-2222 (benzoyl-Ile-Glu (Glu-γ-methoxy)-Gly-Arg-
pNA_HCl), S-2288 (H-D-Ile-Pro-Arg-pNA·2HCl) and S-2238 (H-D-Phe-Pip-Arg-
pNA·2HCl) were from Chromogenix (Milano, Italy). Spectrozyme® FIXa was from 
American Diagnostica Inc (Connecticut, USA). Phosphatidyl choline: phosphatidyl 
serine (PCPS) (7:3) was purchased from Avanti Polar Lipids Inc (Alabama, 
USA). Human plasma was obtained from healthy volunteers through Tissue 
Repository (National University Hospital, Singapore). Superdex 30 HiLoad (16/60) 
column and Jupiter C18 (5 µ, 300 Å, 4.6 × 250 mm) were purchased from GE 
Healthcare (Uppsala, Sweden) and Phenomenex (City, California, USA), respectively. 
All other chemicals and reagents used were of the highest purity.  
2.2.2. Purified blood coagulation proteins  
The blood coagulation factors human FVIIa, FX, FXa, FVa, FIXa, prothrombin, α-
thrombin and Russell’s Viper Venom Factor X activator (RVV-X) were from 
Haemtech (Vermont, USA). Human FVIII was purchased from American Diagnostica 
Inc (Connecticut, USA). Recombinant human tissue factor (TFPL) (Innovin) was 
purchased from Dade Behring (Marburg, Germany). Recombinant human soluble TF 
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(sTF1–218) was a gift from Dr. Toshiyuki Miyata (National Cardiovascular Center, 
Suita, Japan).  
2.2.3. Preparation of phospholipid vesicles  
The single unilamellar vesicles (SUV) of PCPS (7:3) in 50 mM HEPES, pH 7.4 was 
prepared with minor modifications by sonication as per the procedure of Huang 
(Huang, 1969).  Briefly, PCPS in the vial subjected to a stream of N2 gas stream was 
weighed out to make a final concentration of 5 mg/ml in 50 mM HEPES, pH 7.4. The 
cloudy suspension due to large, multilamellar vesicles formed was subjected to 
sonication on a bath sonicator for 1 h. The clear solution thus obtained having SUV 
was stored at 4ºC for further studies.  
2.2.4. Purification of exactin 
 
H. haemachatus crude venom (100 mg in 1 ml of distilled water) was size-
fractionated by gel-filtration chromatography using a Superdex 30 column (1.6 × 60 
cm) equilibrated with 50 mM Tris-HCl buffer (pH 7.4) and eluted with the same 
buffer using an ÄKTA purifier system (GE Healthcare, Uppsala, Sweden). Fractions 
under each peak were pooled and its effect on PTT time was analyzed (discussed 
below). Peak 3 from gel-filtration chromatography that exhibited prolongation of PTT 
was sub-fractionated by RP-HPLC on a Jupiter C18 column (4.6 × 250 mm) 
equilibrated with 0.1% TFA. The bound proteins were eluted using a linear gradient 
of 80% acetonitrile in 0.1% TFA at a flow rate of 2 ml/min. The elution was 
monitored at 215 nm. The individual fractions were collected, lyophilized and 
reconstituted in activation buffer (50 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM 
CaCl2, 1% BSA). The inhibitory effects of these fractions were examined on FX 
activation by the reconstituted extrinsic tenase complex (discussed below). The peak 
corresponding to exactin was re-chromatographed using a shallow gradient on the 
same column. The homogeneity and mass of exactin were checked using ESI-MS 
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performed on API-300 LC/MS/MS system (Perkin-Elmer Sciex, Connecticut, USA). 
The samples were delivered by direct injection. LC-10AD liquid chromatography 
system (Shimadzu, Kyoto, Japan) was used for solvent delivery (50% acetonitrile in 
0.1% FA) at a flow rate of 40 µl/min. Ionspray, orifice and ring voltages were 
typically set at 4600 V, 50 V and 350 V, respectively. Nitrogen was used as nebulizer 
and curtain gas. Analyst software 1.4.1 was used to analyze and deconvolute the raw 
mass data. Purified exactin fractions were thus pooled and freeze-dried.  
2.2.5. N-terminal sequencing 
 
N-terminal sequencing of the native protein was performed by automated Edman 
degradation using an ABI Procise 494 protein sequencer (Applied Biosystems, 
California, USA) with an on-line 785A phenylthiohydantoin derivative analyzer. 
Samples were loaded onto a glass filter pre-coated with Biobrene resin (Applied 
Biosystem, California, USA) dried off under argon and introduced into the sequencer. 
The phenylthiohydantoin amino acids were sequentially identified by mapping the 
respective separation profiles with the standard chromatogram. The number of 
cysteine residues in the native protein was identified by reduction and 
pyridylethylation of the protein and examining its modified mass in ESI-MS. 
2.2.6. Reduction and pyridylethylation 
In order to determine the number of cysteine residues in the native exactin, the protein 
was reduced and pyridylethylated using procedure described previously (Joseph et al., 
1999). Briefly, 0.8 mg of exactin was dissolved in 350 μl of the denaturant buffer 
(0.13 M Tris-HCl, pH 8.5, 1 mM EDTA, 6 M guanidine hydrochloride). After the 
addition of 0.74 μl of β-mercaptoethanol, the mixture was incubated under stream of 
N2 gas for 3 h at 37ºC. 4-Vinylpyridine (3.4 μl) was added to the mixture and kept at 
room temperature for 2 h under N2. S-pyridylethylated protein was purified on an 
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analytical Jupiter C18 column (4.6 × 250 mm) using a linear gradient of 80 % 
acetonitrile at a flow rate of 1 ml/min. The modified mass of exactin was examined in 
ESI-MS.  Cysteine residues in the amino acid sequence were identified by similarity 
with other 3FTxs. [Note: the amount of β-mercaptoethanol and 4-vinylpyridine were 
calculated assuming that the native protein contains 5 disulfide linkages] 
2.2.7. CD spectroscopy 
Far-UV CD spectra (260–190 nm) of exactin, haditoxin and β-cardiotoxin (0.5 
mg/ml) were recorded using a Jasco J-810 spectropolarimeter (Jasco Corp., Tokyo, 
Japan). All the proteins were dissolved in 5 mM phosphate buffer, pH 7.4 and the 
measurements were carried out at room temperature using a 0.1 cm path length 
stoppered cuvette. The instrument optics was flushed with 30 liters of nitrogen 
gas/min. The spectra were recorded using a scan speed of 50 nm/min, a resolution of 
0.2 nm, and a bandwidth of 2 nm. A total of four scans were recorded and averaged 
for each spectrum, and the base line was subtracted. 
2.2.8. Effect of exactin on plasma clotting times 
To identify the specific steps in coagulation cascade that are inhibited, the dissection 
approach (Kini and Banerjee, 2005) was used and the effects of exactin on the four 
clotting times were examined. The fibrin clot formation was monitored using a 
microplate coagulation test method (Pratt and Monroe, 1992). All the experiments 
were done at 37 ºC and the fibrin clot formation was monitored using a 96-well 
microplate reader (Tecan Sunrise, Männedorf, Switzerland) for 10 min at 650 nm 
(unless otherwise stated). The effect of various concentrations of exactin (1 µM to 
300 µM) dissolved in 50 mM Tris-HCl buffer, pH 7.4 were studied on prothrombin 
time (Quick, 1935), Stypven time (Hougie, 1956), thrombine time (Jim, 1957) and 
activated partial thromboplastin time (APTT) (Proctor and Rapaport, 1961).  
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2.2.8.1. Prothrombin time 
Briefly, 100 µl of plasma, 25 µl of 50 mM Tris-HCl, pH 7.4 and 50 µl of various 
concentrations of exactin were incubated for 5 min. The clotting was initiated by the 
addition of 25 µl pre-warmed thromboplastin (with calcium) reagent and the fibrin 
clot formation was monitored.  
2.2.8.2. Stypven time 
In a reaction well, 50 µl of plasma was incubated with 50 µl of various concentrations 
of exactin for 3 min. 50 µl of RVV-X (10 ng/ml) was added and incubated for another 
2 min. The clotting was initiated by the addition of 50 µl of 25 mM pre-warmed 
CaCl2 and the fibrin formation was monitored. 
2.2.8.3. Thrombin time 
Equal volumes of plasma, 50 mM Tris-HCl, pH 7.4 and various concentrations of 
exactin (50 µl) were incubated together for 5 min followed by the addition of 50 µl 
pre-warmed thrombin time reagent (0.15 NIH units) and the fibrin formation was 
monitored.  
2.2.8.4. Activated partial thromboplastin time (APTT) 
The effect of exactin on APTT was studied by incubating equal volumes (50 µl) of 
plasma and various concentrations of exactin for 3 min. Pre-warmed APTT reagent 
(50 µl ) was added and further incubated for 2 min after which the clotting was 
initiated by the addition of 50 µl pre-warmed 25 mM CaCl2 and the fibrin clot 
formation was monitored. 
2.2.9. Effect of exactin on FX activation by extrinsic tenase complex  
All the reactions were carried out at 37ºC. In a reaction volume of 200 µl, the 
extrinsic tenase complex was reconstituted by incubating 10 pM of human FVIIa with 
Innovin in an activation buffer (50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 
 84 
 
1% BSA) for 15 min. After 15 min incubation with various concentrations of exactin 
(25 µl of 300 pM to 10 µM), 25 µl of FX was added to make a final concentration of 
30 nM. The activation was quenched after 15 min by adding 50 µl of quench buffer 
(50 mM HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 1% BSA). The initial 
reaction velocity of S-2222 cleavage by FXa formed in the reaction mixture was 
measured by the hydrolysis of 50 µl of 500 µM of S-2222 in a microplate reader at 
405 nm. The amount of FXa generated at each concentration of exactin was measured 
from a FXa standard curve. FXa formed in the absence of inhibitor was considered as 
100% and the IC50 concentration was determined. 
2.2.10. Effect of exactin on FX activation by intrinsic tenase complex 
The intrinsic tenase complex (FIXa/FVIIIa)PL was reconstituted according to the 
method of Zhang et al. with minor modifications (Zhang et al., 1998). Briefly, all the 
reactions were carried out in 50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 1% 
BSA having 67 µM of reconstituted PCPS at 37 
º
C. In a reaction volume of 200 µl, 
FVIII (5 nM) was incubated for 10 min with thrombin (500 pM) and the reaction was 
quenched by the addition of 25 µl hirudin (115 units/ml/well), a thrombin inhibitor. 
To this 25 µl FIXa was added to make a final concentration of 1 nM. After 10 min, 
varying concentration of exactin (25 µl of 30 nM to 300 µM) was added and 
incubated for 15 min. The substrate, 25 µl FX was added to make a final 
concentration of 25 nM. The reaction was stopped after 15 min by adding the quench 
buffer 50 mM HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 1% BSA. The 
hydrolysis of 25 µl of 500 µM S-2222 by the FXa formed was measured at 405 nm. 





2.2.11. Effect of exactin on FX activation by RVV-X 
All the reactions were carried out in 50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM 
CaCl2, 1% BSA at 37 ºC. 50 µl of exactin (300 pM -10 µM) was incubated with 25 µl 
of RVV-X (100 pM) in a 200 µl 96-well plate for 15 min. The FX activation was 
initiated by the addition of 25 µl FX (12.5 nM). The FXa formation was quenched 
after 15 min by the addition of 50 µl of quench buffer (50 mM HEPES pH 7.4, 140 
mM NaCl, 50 mM EDTA, 1% BSA) and the hydrolysis of 50 µl of 500 µM S-2222 
by FXa generated was measured at 405 nm. The IC50 value was calculated similar to 
that mentioned in section 2.2.9. 
2.2.12. Effect of exactin on prothrombin activation by prothrombinase complex  
The assay was carried out in 50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 1% 
BSA at 37ºC. The PCPS concentration used was 67 µM. In a 200 µl 96-well plate, 
varying concentration of exactin (50 µl of 30 nM to 300 µM) was added to a 
reconstituted FXa (10 pM) – FVa (1 nM) complex (prothrombinase complex) and 
incubated for 15 min. Prothrombin (25 µl of 12.5 nM) was added and incubated for 
another 15 min. The reaction was quenched by adding 50 mM HEPES pH 7.4, 140 
mM NaCl, 50 mM EDTA, 1% BSA. The hydrolysis of 50 µl of 250 µM S-2238 by 
thrombin generated in the reaction mix was measured in a multiplate reader at 405 
nm. The IC50 value was calculated by determining thrombin generated from a 
standard curve, considering that thrombin generated in the absence of inhibitor is 
100%. 
2.2.13. Effect of exactin on FIX activation by extrinsic tenase complex 
The dose-response effect of exactin (0.01 µM to 300 µM) on FIX activation by 
extrinsic tenase complex was examined at 37 
º
C in an activation buffer (50 mM 
HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 1% BSA). Briefly, the extrinsic tenase 
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complex was reconstituted from 1 nM FVIIa and Innovin. The tenase complex was 
incubated with various concentrations of exactin (25 µl). FIX was then added to the 
reaction mix to make a final concentration of 600 nM (25 µl). After 15 min of 
incubation, the reaction was quenched by adding EDTA buffer and the hydrolysis of 
the chromogenic substrate, 100 µl of Spectrozyme FIXa (1 mM) by FIXa generated in 
the reaction mixture was measured at 405 nm. From a FIXa standard curve, the 
amount of FIXa formed at each concentration of exactin was measured. This was used 
to determine the IC50 value, considering FIXa generated in the absence of inhibitor as 
100%.  
2.2.14. Mechanism of inhibition of the extrinsic activation complex  
To understand the mechanism of inhibition, we studied the effects of exactin (30 nM 
to 300 µM) on the activation of FX by FVIIa/sTF complex and by FVIIa (in the 
presence or absence of PLs). We also examined the kinetics of inhibition when 
appropriate. An activation buffer (50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM 
CaCl2, 1% BSA) and a quench buffer (50 mM HEPES pH 7.4, 140 mM NaCl, 50 mM 
EDTA, 1% BSA) was used for all the experiments. All the incubations were at 37ºC. 
To examine the role of PLs, FVIIa (10 nM) and sTF (30 nM) in activation buffer 
containing 2.5 mM MgCl2 (Persson and Østergaard, 2007) was incubated with various 
concentrations of exactin (50 µl) for 15 min before the addition of 25 µl FX (2 µM 
final concentration). To examine the role of TF, 25 µl of FVIIa (10 nM and 20 nM in 
activation buffer with or without PCPS [67 µM] in the absence of TF, respectively) 
was incubated with various concentrations of exactin (50 µl) for 15 min. FX (25 µl) 
was added to make a final concentration of 640 nM. In all experiments, the reaction 
was quenched after 15 min of FX activation by the addition of EDTA buffer and the 
amount of FXa formed was measured similar to that mentioned in section 2.2.9. 
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2.2.15. Effect of exactin on FVIIa, FXa, FIXa and thrombin amidolytic activity 
The amidolytic activities of various serine proteases with exactin were studied at 37ºC 
in the presence of the activation buffer (50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM 
CaCl2, 1% BSA). In a total volume of 200 µl in the individual wells of a 96-well plate, 
the effect of exactin (0.03 µM to 300 µM) on final concentrations of FVIIa [in 
presence of sTF (FVIIa- 10 nM, sTF-30 nM), without sTF (FVIIa-300 nM)], FXa (1 
nM), FIXa (300 nM) and α-thrombin (3 nM) were examined. The chromogenic 
substrates S-2288 (500 µM), S-2222 (1 mM), Spectrozyme FIXa (1 mM) and S-2238 
(250 µM) were used respectively. The rate of substrate hydrolysis was measured at 
405 nm. 
2.2.16. Kinetics of inhibition of extrinsic complex mediated FX activation  
The inhibitory kinetics (with exactin) of extrinsic tenase complex, FVIIaPL and 
FVIIa/sTF mediated FX activation was determined. All the reactions were carried out 
in an assay buffer of 50 mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 1% BSA 
(except for kinetic studies with FVIIa/sTF where the activation buffer contained 2.5 
mM MgCl2) at 37 ºC and the quench buffer used was 50 mM HEPES pH 7.4, 140 
mM NaCl, 50 mM EDTA, 1% BSA. The inhibitory action of exactin was examined 
over a wide range of substrate concentrations. For FX activation by extrinsic tenase 
complex, varying concentration of FX (0.58 nM – 50 nM) were added to individual 
wells of a 96-well plate containing FVIIa (10 pM) in complex with Innovin and 
exactin (0 nM, 30 nM, 100 nM and 300 nM). After 15 min, FXa generation was 
quenched and the rate of hydrolysis of 500 µM S-2222 was measured at 405 nm over 
5 min.  
For kinetic studies in the absence of PLs, the effect of exactin (0 µM, 100 µM and 
300 µM) on FX (0.025 μM to 5 μM) activation by FVIIa (10 nM) and sTF (30 nM) 
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was examined. In case of FX activation by FVIIa in the presence of PLs and absence 
of TF, FX (11.4 nM to 1 µM) with 10 nM FVIIa and 67 µM PCPS was used. The 
exactin concentrations used were 0 nM, 30 nM, 100 nM and 300 nM. The 
experimental design was same as the above. The rate of FXa formed at each 
concentration of FX was measured from a standard curve. 
2.2.17. Kinetics of inhibition of intrinsic tenase mediated FX activation  
All the reactions were carried out in an assay buffer of 50 mM HEPES pH 7.4, 140 
mM NaCl, 5 mM CaCl2, 1% BSA at 37 ºC and the quench buffer used was 50 mM 
HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 1% BSA. The inhibitory action of 
exactin (0 μM, 3 μM, 5 μM and 10 μM) was examined over a wide range of substrate 
(FX) concentrations (1 nM - 1 μM). The experimental procedure was similar to that 
mentioned in 2.2.10 
2.2.18. Kinetics of inhibition of RVV-X mediated FX activation  
All the reactions were carried out in an assay buffer of 50 mM HEPES pH 7.4, 140 
mM NaCl, 5 mM CaCl2, 1% BSA at 37 ºC and the quench buffer used was 50 mM 
HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 1% BSA. The inhibitory action of 
exactin (0 μM, 3 μM, 5 μM and 7 μM) was examined over a wide range of substrate 
(FX) concentrations (1 nM - 1 μM). The experimental procedure was similar to that 
mentioned in 2.2.11. 
2.2.19. Kinetics of inhibition of extrinsic tenase mediated FIX activation  
Inhibitory kinetics (with exactin) of extrinsic tenase mediated FIX activation was 
determined. The experimental procedure was similar to section 2.2.13. Briefly, 
exactin (0 µM, 10 µM, 30 µM and 100 µM) was incubated with reconstituted 
extrinsic tenase complex formed from 1 nM FVIIa and Innovin. Varying 
concentrations of FIX (0.025 µM to 5 µM) was then added to the reaction mixture. 
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After 15 min of incubation, the reaction was quenched and the rate of hydrolysis of 1 
mM Spectrozyme FIXa was monitored at 405 nm over 5 min. The rate of FIXa 
formed at each concentration of FIX was measured from a standard curve. 
2.2.20. Data analysis with kinetics of inhibition  
Data obtained from the inhibition studies with exactin were fitted to the following 
equation for mixed-type inhibition (Silverman, 2002) to determine the Ki and Ki’ 
values. 
 
To determine the Ki and Ki’ values, the data from the Lineweaver-Burk plot were re-
plotted as Km/Vmax {1+ [I]/Ki} (the slope) versus [I] or as 1/Vmax app. (the y-axis 
intercept) versus [I] respectively. The x-axis intercept for the respective plots would 
give Ki and Ki’. Ki denotes the affinity of inhibitor towards the enzyme while Ki’ 
















2.3.1. Purification of exactin 
The crude venom was size-fractionated by gel-filtration chromatography into five 
peaks (Fig. 2.2). The anticoagulant property of each peak was analyzed by evaluating 
its effect on the prolongation of plasma prothrombin time. Peak 2 and 3 exhibited a 
significant dose-dependent prolongation of prothrombin time (inset). The peak 3 
(from SEC) was further fractionated on a C18 RP-HPLC column. Fig. 2.3 represents 
the RP-HPLC chromatogram of peak 3 on to which the inhibitory effect of each 
fraction on FX activation by the extrinsic tenase complex was overlaid. The elution 
profile indicated the presence of several inhibitors of the extrinsic activation complex. 
Some of these inhibitors were partially characterized, an account of which has been 
described in this chapter. In the current study, focus was given for the purification and 
characterization of exactin (Extrinsic Activation Inhibitor) (peak highlighted by a 
black arrow). This peak was further re-chromatographed using a shallow gradient on 
the same column (Fig. 2.4A). The homogeneity and mass of the purified 
anticoagulant protein exactin was determined by ESI-MS. The mass spectra showed 3 
peaks of mass/charge (m/z) ratio ranging from +4 to +6 charges (Fig. 2.4B) and the 










































































Figure 2.2: Purification of exactin: SEC. The crude venom of H. 
haemachatus was size-fractionated into five peaks. Peak 2 and 3 
significantly prolonged the plasma clotting time (inset) as determined 
by prothrombin time. Peak 2 mainly corresponds to snake venom 
































































Figure 2.3: Purification of exactin: RP-HPLC. The peak 3 of SEC 
corresponding to the non-enzymatic 3FTXs, were subjected to RP-
HPLC on a Jupiter C18 column (4.6 × 250 mm). A linear gradient of 
28-50% of solvent B (green line) was used. Each fraction collected 
were freeze-dried and reconstituted in a calcium buffer. The inhibitory 
effect of each fraction towards FX activation by the extrinsic tenase 
complex was evaluated. The red line corresponds to % inhibition of 
FX activation that is overlaid on to the chromatogram. A number of 
inhibitors have been found, but the purification and functional 
characterization of exactin (black arrow) was carried out. We also 
partially characterized other anticoagulants, highlighted as blue arrow 


























































































Figure 2.4: Purification of exactin to homogeneity. A) Re-
chromatography of exactin. Exactin was purified on a shallow 
gradient of 28%-35% of solvent B (green line) on a Jupiter C18 
column (4.6 × 250 mm). B) ESI-MS profile of exactin. The 
homogeneity and mass of the purified protein was determined in 
ESI-MS. The molecular mass of exactin was determined as 





2.3.2. N-terminal sequence determination 
The complete amino acid sequence of exactin was determined by automated Edman 
degradation. Exactin had 57 amino acid residues. The calculated mass of 6621.5 Da 
from the sequence of native exactin coincides well with the observed molecular mass 
of 6621.12 Da. Since the “native” exactin was sequenced, the number of cysteinyl 
residues in exactin was determined via reduction and pyridylethylation and 
determining the mass in ESI-MS. An observed mass of 7470.91 ± 1.6 Da (Fig. 2.5) 
for the reduced and pyridylethylated exactin denotes the presence of eight cysteinyl 
residues. The amino acid sequences of the proteins were subjected to a similarity 
search using BLAST (Altschul et al., 1997). Multiple sequence alignment was carried 
out. The sequence data of the homologus proteins were obtained from PDB (Protein 
Data Bank) database. Sequence alignment showed that exactin belongs to the 3FTx 
family based on the number and position of cysteine residues. It showed 82% identity 
to weak toxin CM1b isolated from H. haemachatus venom (Fig. 2.6A). It also showed 
identity (>58%) to a number of O. hannah (king cobra) neurotoxins. Interestingly, 
exactin showed low identity (< 35 %) to other well characterized anticoagulant 3FTxs 
(naniproin, hemextin and siamextin) (Fig. 2.6B). 
2.3.3. CD spectroscopy  
Exactin showed intense minima at 212 nm and 194 nm and maxima at 200 nm (Fig. 
2.7). Like other 3FTxs - β–cardiotoxin (Rajagopalan et al., 2007) and haditoxin (Roy 















































Figure 2.5: Determination of number of cysteinyl residues in exactin. Since 
the complete sequence of exactin was derived by direct sequencing of the native 
protein, number of cysteinyl residues were determined from the mass of reduced 
and pyridylethylated exactin. A mass of 7470.91 ± 1.6 Da confirms the presence 








Exactin    LECYQKSKVVTCQPEQKFCYSDTTMFFPNHPVYLSGCTFSCTEEGN-RRCCTTDKCNR----     
CM-1b      LECYQKSKVVTCQPEQKFCYSDTMTFFPNHPVYLSGCTF-CRTDESGERCCTTDRCNK----        82        
CM-2a      LECYQMSKVVTCKPEEKFCYSDVFMPFRNHIVYTSGCSSYCR-DGTGEKCCTTDRCNGARGG        65       
CM-3       LECYQMSKVVTCKPEEKFCYSDVFMPFRNHVYTS-GCSSYCRDGTGEK-CCTTDRCNGARGG        65       
Oh9-1      LICHRVHGLQTCEPDQKFCFRKTTMFFPNHPVLLMGCTSSCPTEKYSV-CCSTDKCNK----        58       
Oh-26      LICHQRHGLQTCEPAQKFCFAQTVMPFPNHPLTLMGCTYSCPTEKNAV-CCSTDKCNR----        58       
Oh-5       LICHRVHGLQTCEPDQKFCFRKTTMFFPNHPVLLMGCTYSCPTEKYSV-CCSTDKCNK----        58       
sntx11     LICHRVHGLQTCEPDQKFCFRKTTMFFPNHPVLLMGCTYSCPTEKYSV-CCSTDKCNK----        58       
sntx14     LICHQLHGLQTCEPAQKFCQKRTTMFFPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK----        58       
sntx26     LICHQVHGLQTCEPAQKFCQKRTTMFFPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK----        58       
Oh-46      LICHQVHGLQTCEPAQKFCQIRTTMFFPNHPVLLMGCTYNCPTERYSV-CCSTDKCNK----        58       
 
 
Exactin        LECYQKSKVVT---CQPEQKFCYSDTTMFFPNHPVYLSGCTFSCTEEGN---RRCCTTDKCNR  
Naniproin      LKCNRLIPPFWKT-CPEGKNLCYKMTMRLAPKVPVKRG-CIDVCPKSSLLIKYMCCTNDKCN    35 
Hemextin A     LKCHNKLVPFLSKTCPEGKNLCYKMTMLKMPKIPIKRG-CTDACPKSSLLVKVVCCNKDKCN    35 



















Figure 2.6: Sequence alignment of exactin. The homology of each of the 
sequence in (% Id) identity is given. The conserved eight cysteine residues as well 
as the identical residues among the sequences are highlighted in black. A) 
Comparison was made with the following sequences: CM-1b from H. 
haemachatus; CM-2a and CM-3 from N. haje annulifera; Oh9-1, Oh-26, Oh-5, Oh-
46, short neurotoxin (sntx) 11, sntx14 and sntx26 were from O. hannah. B) 
Sequence comparison of exactin with other anticoagulant 3FTxs. The comparison 
was made with hemextin A from H. haemachatus; naniproin from N. nigricollis 














































Figure 2.7: CD spectra of exactin. The CD spectra of exactin were 
compared with that of haditoxin and β-cardiotoxin (0.5 mg/ml) from O. 
hannah. Exactin showed predominantly β-sheet structure with intense 
minima at 212 nm and 194 nm and a maximum at 200 nm. 
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2.3.4. Anticoagulant site of exactin 
A ‘dissection approach’ (Kini and Banerjee, 2005) was used to understand exactin’s 
target in the blood coagulation cascade. Exactin significantly prolonged prothrombin 
time compared to Stypven time and APTT (Fig. 2.8A). However, it did not have any 
effect on thrombin time. The results suggest that exactin specifically targets the 
extrinsic complex. To further validate the target complex, we determined the effects 
of exactin on the reconstituted extrinsic tenase, intrinsic tenase and prothrombinase 
complexes as well as thrombin (Fig. 2.8B). Exactin specifically inhibited FX 
activation by reconstituted extrinsic tenase compared to intrinsic tenase complex with 
IC50 values of 116.49 ± 3.28 nM and 4.05 ± 0.32 µM, respectively. It also inhibited 
prothrombin activation by prothrombinase complex with an IC50 value of 17.66 ± 0.58 
µM but it did not affect thrombin amidolytic activity. The thus results suggest that 
exactin specifically targets the extrinsic activation complex in the coagulation 
cascade. 
2.3.5. Mechanism of action of exactin 
To understand the molecular mechanism, the effect of exactin was examined in 
various assays where each part of the extrinsic tenase complex was removed 
sequentially. In the first step, TF was removed and the effect of exactin on the 
activation of FX by FVIIa in the presence of PL was studied. The removal of TF did 
not affect the inhibitory potency of exactin (IC50 value 102.70 ± 11.71 nM compared 
to 116.49 ± 3.28 nM for the complete complex) (Fig. 2.9A). However, with exactin a 
very low percent activation of FX by FVIIa was observed in the absence of both TF 
and PL (Fig. 2.9A inset). In the second step, we examined the effect of exactin on the 



























































Figure 2.8: Anticoagulant site of exactin. A) The effect of exactin on the 
four blood clotting times was evaluated. These were prothrombin time ( ), 
APTT ( ), Stypven time ( ) and thrombin time ( ). Exactin prolonged 
prothrombin time more significantly compared to others suggesting its target 
as extrinsic activation complex. B) The effect of exactin was evaluated on the 
reconstituted blood coagulation complexes as well as thrombin. The IC50 
values were determined for the following: inhibition of FX activation by 
extrinsic tenase complex ( ) was found to be 116.49 ± 3.28 nM; inhibition of 
FX activation by intrinsic tenase complex ( ) was found to be 4.05 ± 0.32 
µM; inhibition of PT activation by prothrombinase complex ( ) was found to 
be 17.66 ± 0.58 µM and finally the effect on thrombin amidolytic activity 
( ). Exactin exhibited >30 and >150-folds inhibitory activity to extrinsic 
tenase when compared to intrinsic and prothrombinase complex activity, 
respectively. Also exactin did not inhibit thrombin, suggesting its preferable 
site of anticoagulant activity as ‘extrinsic activation complex’. All the 


































































Figure 2.9: Mechanism of action. A) The effect of exactin on 
the sequential removal of each component of the extrinsic 
activation complex was analysed. Removal of TF did not alter the 
inhibition of exactin towards FX activation. The IC50 value of 
102.70 ± 11.71 nM obtained with FX activation by FVIIaPL ( ) 
was comparable to that with extrinsic tenase complex ( ) (IC50 - 
116.49 ± 3.28 nM). Removal of PLs drastically reduced the 
inhibition by > 1000-folds ( ). A low percent activation was 
observed when exactin’s effect was evaluated on FX activation by 
FVIIa in the absence of both TF and PLs (inset). B) The effect of 
exactin on FVIIa and FXa amidolytic activity: FVIIa/sTF ( ); 
FVIIa ( ); FVIIaPL ( ) and FXa ( ). Exactin failed to inhibit the 
amidolytic activities of the serine proteases FVIIa and FXa, 
suggesting its full potency towards the entire extrinsic activation 
complex. All the experiments were conducted in n=3 and the 






The inhibitory potency of exactin was drastically reduced by >1000-fold (Fig. 2.9A). 
We also examined the effect of exactin on the amidolytic activity of FVIIa (with sTF, 
with PL and in the absence of both sTF and PLs) and FXa. As shown in Fig. 2.9B, 
exactin is a poor inhibitor of both these enzymes (IC50 values >300 µM). Taken 
together, exactin preferably inhibits the macromolecular substrate complex with 
FVIIA/TFPL (extrinsic activation complex).  
2.3.6. Kinetics of inhibition of extrinsic activation complex by exactin 
To further understand the interactions, the inhibition kinetics of exactin on FX 
activation by the complete extrinsic tenase complex, FVIIa in the presence of PL and 
FVIIa in the presence of sTF were examined. In all the kinetic studies the kinetic 
constants Ki’, Ki as well as the kinetic parameters, KM and Kcat (number of moles of 
substrate converted to product per mole of enzyme per min) were determined (Table 
2.1, 2.2 and 2.3). Exactin exhibited mixed-type inhibition of FX activation by the 
complete extrinsic tenase complex (Fig. 2.10B) as well as FVIIa in the presence of PL 
(Fig. 2.11B).  Lineweaver-Burk plots exhibited a decrease in both KM and Vmax with 
increase in inhibitor concentration, typical of mixed-type inhibition. The kinetic 
constants, Ki’ and Ki derived from the secondary plot were found to be  30.62 ± 7.73 
nM and 153.75 ± 17.96 nM for FX activation by extrinsic tenase complex (Fig. 
2.10C,D). The Ki’ and Ki for FX activation by FVIIa in the presence of PL was 103 ± 
13.49 nM and 184.25 ± 6.13 nM, respectively (Fig. 2.11C,D). The affinity of the 
inhibitor towards the enzyme-substrate complex (FVIIa/TF/FX/PL, Ki’ 30.62 ± 7.73 
nM) was 5-fold higher compared to the enzyme complex (FVIIa/TF/PL, Ki 153.75 ± 
17.96 nM) suggesting its preference to [ES] complex. In the absence of TF, Ki’ 
dropped 3-fold to 103 ± 13.49 nM with a slight decrease in Ki of 184.25 ± 6.13 nM. 
Thus, exactin appears to bind to the complete complex better than FVIIa/FX complex. 
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Exactin weakly inhibited the extrinsic activation complex in the absence of PL and 
exhibited a mixed-type inhibition as from the Lineweaver-Burk plot (both KM and 
Vmax decreased with increase in inhibitor concentration) (Fig. 2.12B) with the kinetic 
constants Ki’ and Ki of 158.66 ± 28 μM and 1153.33 ± 49.32 μM respectively (Fig. 
2.12C,D). Thus, as expected, the affinity towards the enzyme-substrate complex 
(FVIIa/sTF/FX) and enzyme (FVIIa/sTF) decreased by >1000-fold, suggesting its 
preference towards membrane-bound complex. As FX activation by FVIIa in the 
absence of TF and PL was too low, the effect of exactin on FX activation by FVIIa 


























































































Figure 2.10: Kinetics of inhibition of FX activation by extrinsic 
tenase complex. A) Schematic representation of the extrinsic 
activation complex (FVIIa/TF/FX on phospholipid membrane). B) 
The Lineweaver-Burk plot for the kinetic activity of FX activation 
by FVIIa/TFPL in the presence of exactin (0 nM, 30 nM, 100 nM 
and 300 nM). Both Vmax and KM decreased with increase in 
inhibitor concentration, characteristic of mixed-type inhibition. C 
and D) Corresponding secondary plots depicting kinetic constants 
Ki’ and Ki for inhibition. Ki’ of 30.62 ± 7.7 nM was obtained 
towards the enzyme-substrate complex (FVIIa/TFPL/FX) where as 
Ki of 153.75 ± 17.96 nM was obtained towards the enzyme 
(FVIIa/TFPL). All the experiments were conducted n=5 and the 










































































Figure 2.11: Kinetics of inhibition of FX activation by FVIIa in 
the presence of phospholipids. A) Schematic representation of the 
complex (FVIIa/FX on phospholipid membrane). B) The 
Lineweaver-Burk plot for the kinetic activity of FX activation by 
FVIIaPL in the presence of exactin (0 nM, 30 nM, 100 nM and 300 
nM). Both Vmax and KM decreased with increase in inhibitor 
concentration, characteristic of mixed-type inhibition. C) and D) 
Corresponding secondary plots depicting kinetic constants Ki’ and 
Ki for inhibition. Ki’ of 103 ± 13.49 nM was obtained towards the 
enzyme-substrate complex (FVIIa/FX)PL where as Ki of 184.25 ± 
6.13 nM was obtained towards the enzyme (FVIIaPL). All the 
experiments were conducted in n=5 and the results were expressed 


















































































Figure 2.12: Kinetics of inhibition of FX activation by 
FVIIa/sTF. A) Schematic representation of FVIIa/sTF/FX 
complex. B) The Lineweaver-Burk plot for the kinetic activity of 
FX activation by FVIIa/sTF in the presence of exactin (0 µM, 100 
µM and 300 µM). Both Vmax and KM decreased with increase in 
inhibitor concentration, characteristic of mixed-type inhibition. C 
and D) Corresponding secondary plots depicting kinetic constants 
Ki’ and Ki for inhibition. Ki’ of 295 ± 7.07 µM was obtained 
towards the enzyme-substrate complex (FVIIa/sTF/FX) where as Ki 
of 1250 ± 56.56 µM was obtained towards the enzyme (FVIIa/sTF). 
All the experiments were conducted in n=3 and the results were 












Table 2.1: Kinetic parameters for FX activation by extrinsic tenase complex 
Exactin
(nM)
Km (nM) Kcat (s-1) Kcat/Km
(s-1 nM-1)
0 14.57 ± 0.87 1.7 ± 0.017 0.117 ± 0.055
30 8.31 ± 0.72 0.95 ± 0.98 0.114 ± 0.008
100 6.46 ± 1.98 0.623 ± 0.2 0.095 ± 0.012
300 5.66 ± 1.9 0.32 ± 0.124 0.057 ± 0.013
 
 Table 2.2: Kinetic parameters for FX activation by FVIIaPL 
Exactin
(nM)
Km (nM) Kcat (s-1) Kcat/Km
(s-1 nM-1)
0 36.56 ± 2.76 0.0558 ± 0.0046 0.0014 ± 0.00014
30 23.75 ± 2.71 0.0346 ± 0.0026 0.0014 ± 0.0002 
100 18.37 ± 1.49 0.0262 ± 0.0035 0.0014 ± 0.0002
300 12.22 ± 1.029 0.0151 ± 0.0031 0.0013 ± 0.00026
 
 Table 2.3: Kinetic parameters for FX activation by FVIIa/sTF 
Exactin
(μM)
Km (μM) Kcat (s-1) Kcat/Km
(s-1 μM-1)
0 1.03 ± 0.089 0.0017± 6.13 E-05 0.0016 ± 0.0001
100 0.76 ± 0.126 0.00065 ± 6.01 E-06 0.0009 ± 0.0002







2.3.7. Macromolecular specificities of exactin 
 
Inorder to evaluate the specificity of exactin, the inhibitory potencies towards the 
macromolecular complexes: enzyme (FVIIa/TFPL) and substrate (FX) separately were 
examined.  
2.3.7.1. Specificity of exactin towards the extrinsic tenase complex  
 
The kinetic studies have shown that exactin exerts its full inhibitory potency towards 
the entire extrinsic activation complex. Inorder to evaluate the inhibitory specificity of 
exactin towards the FX activator, FX activation by extrinsic tenase complex, intrinsic 
tenase complex and RVV-X was studied (Fig. 2.13). Compared to the FX activation 
by the extrinsic tenase complex (IC50 - 116.49 ± 3.28 nM), exactin exhibited < 30 
folds inhibition to FX activation by both the intrinsic tenase complex and RVV-X 
(IC50 values of 4.05 ± 0.32 µM and 6.1 ± 2.9 µM, respectively).  Thus, the results 
confirm the specificity of exactin towards the extrinsic tenase complex in activating 
FX. To further understand this, the inhibitory kinetics of exactin on FX activation by 
both intrinsic tenase complex as well as the snake venom FX activator (RVV-X) was 
studied.  Exactin exhibited a non-competitive inhibition towards FX activation by 
both intrinsic tenase complex (Fig. 2.14B) and RVV-X (Fig. 2.15B). The kinetic 
parameters (KM and Kcat) determined (Table 2.4, 2.5) showed that the KM remains 
unchanged whereas Vmax decreasaed with increase in inhibitor concentration, typical 
of non-competitive inhibition. The kinetic constants Ki for FX activation by intrinsic 
tenase complex (Fig. 2.14C) and RVV-X (Fig. 2.15C) were determined to be 1.67 ± 












































Figure 2.13: Specificity of exactin towards the extrinsic 
tenase complex. The inhibition of FX activation in the 
presence of exactin was compared among the three FX 
activators: extrinsic tenase complex ( ) (IC50 - 116.49 ± 
3.28 nM); intrinsic tenase complex ( ) (IC50 - 4.05 ± 0.32 
µM) and RVV-X ( ) (IC50 - 6.1 ± 2.9 µM). Exactin 
inhibited FX activation by the extrinsic tenase complex with 
high specificity. All the experiments were conducted in n=3 




































































Figure 2.14: Kinetics of inhibition of FX activation by 
intrinsic tenase complex. A) Schematic representation of the 
intrinsic activation complex (FIXa/FVIIIa/FX). B) The 
Lineweaver-Burk plot for the kinetic activity of FX activation 
by FIXa/FVIIIa in the presence of exactin (0 µM, 3 µM, 5 µM 
and 10 µM). KM remains unchanged while Vmax decreased 
with increase in inhibitor concentration, characteristic of non-
competitive inhibition. C) The corresponding secondary plot 
depicting kinetic constant Ki of 1.67 ± 0.35 µM. All the 
experiments were conducted in n=3 and the results were 






























































Figure 2.15: Kinetics of inhibition of FX activation by RVV-
X. A) Schematic representation of RVV-X bound to FX. B) The 
Lineweaver-Burk plot for the kinetic activity of FX activation 
by RVV-X in the presence of exactin (0 µM, 3 µM, 5 µM and 7 
µM). KM remains unchanged while Vmax decreased with 
increase in inhibitor concentration, characteristic of non-
competitive inhibition. C) The corresponding secondary plot 
depicting kinetic constant Ki of 2.79 ± 0.29 µM. All the 
experiments were conducted in n=4 and the results were 













Table 2.4: Kinetic parameters for FX activation by intrinsic tenase complex 
Exactin
(μM)
Km (nM) Kcat (s-1) Kcat/Km
(s-1 nM-1)
0 4.31 ± 0.62 0.48 ± 0.064 0.11 ± 0.012
3 3.26 ± 0.46 0.07 ± 0.0024 0.021 ± 0.002
5 3.21 ± 0.24 0.042 ± 0.004 0.013 ± 0.002
10 3.23 ± 0.24 0.022 ± 0.004 0.007 ± 0.002
 
Table 2.5: Kinetic parameters for FX activation by RVV-X 
Exactin
(μM)
Km (nM) Kcat (s-1) Kcat/Km
(s-1 nM-1)
0 8.48 ± 1.06 0.85 ± 0.027 0.101 ± 0.01
3 8.49 ± 0.55 0.23 ± 0.044 0.0272 ± 0.006
5 9.19 ± 0.53 0.19 ± 0.023 0.021 ± 0.002










2.3.7.2. Specificity of exactin towards FX 
We have shown that exactin is specific towards the extrinsic tenase complex in 
activating FX when compared to other two activators (intrinsic tenase complex and 
RVV-X). Inorder to understand the macromolecular substrate specificity of exactin, 
the inhibitory potency of exactin towards the activation of FX and FIX by extrinsic 
tenase complex was compared. Both FX and FIX serves as macromolecular substrates 
for the extrinsic tenase complex (Fujikawa et al., 1974; Zӧgg and Brandstetter, 2011). 
Exactin inhibited FIX activation with an IC50 value of 29.66 ± 5.27 µM.  However, 
when compared to FX activation it was >100-fold lower (Fig. 2.16A). Exactin also 
exhibited a mixed-type inhibition towards FIX activation by the extrinsic tenase 
complex (Fig. 2.17B). The kinetic constants Ki’, Ki as well as the kinetic parameters 
(KM and Kcat) (Table 2.6) were determined. The KM and Vmax decreased with 
increase in inhibitor concentration, typical for mixed type inhibition. The kinetic 
constants Ki’ and Ki values were 38.66 ± 10.27 μM and 128.6 ± 12.55 μM (Fig. 2.17 
C,D), respectively. The effect of exactin on the amidolytic activity of FIXa was 
evaluated and found to be significantly lower (IC50 > 300 µM) (Fig. 2.16B). The 
results further support the findings that exactin is a highly specific inhibitor of FX 
























































Figure 2.16: Specificity of exactin towards FX. A) The 
inhibitory potency of exactin towards the activation of the 
two macromolecular substrates (FX and FIX) of extrinsic 
tenase was evaluated. IC50 values of 116.49 ± 3.28 nM and 
29.66 ± 5.27 µM for FX ( ) and FIX activation ( ) were 
determined, respectively. B) The effect of exactin on FIXa 
amidolytic activity was studied. Exactin was a poor 
inhibitor of FIXa. All the experiments were conducted in 





All the experiments were conducted in n=3 and the results 















































































Figure 2.17: Kinetics of inhibition of FIX activation by 
extrinsic tenase complex. A) Schematic representation of 
FVIIa/TF/FIX complex on the phospholipid membrane). B) The 
Lineweaver-Burk plot for the kinetic activity of FIX activation by 
FVIIa/TFPL in the presence of exactin (0 µM, 10 µM and 100 
µM). Both Vmax and KM decreased with increase in inhibitor 
concentration, characteristic of mixed-type inhibition. C and D) 
Corresponding secondary plots depicting kinetic constants Ki’ 
and Ki for inhibition. Ki’ of 38.66 ± 10.27 µM was obtained 
towards the enzyme-substrate complex (FVIIa/TFPL/FIX) where 
as Ki of 128.6 ± 12.54 µM was obtained towards the enzyme 
(FVIIa/sTF). All the experiments were conducted in n=3 and the 
















 Table 2.6: Kinetic parameters for FIX activation by extrinsic tenase complex 
Exactin
(μM)
Km (nM) Kcat (s-1) Kcat/Km
0 299.13 ± 7.84 1.34 ± 0.012 0.0044 ± 0.00015
10 231.83 ± 6.83 0.94 ± 0.0007 0.004 ± 0.0001
30 189± 11.72 0.744 ± 0.018 0.0039 ± 0.00017














2.3.8. Partial characterization of other extrinsic activation inhibitors 
Initial screening for anticoagulants from the crude venom of Hemachatus has yielded 
many inhibitors targeting the FX activation by the tenase complex (Fig. 2.3). A few of 
the inhibitors were purified and IC50 values determined. Currently, the structural and 
functional characterizations of these inhibitors are being carried out. Since these 
anticoagulants are not named, they will be denoted by their respective masses. 
Anticoagulant proteins from Peak 2 (blue arrow), peak 6 (brown arrow) and peak 10 
(green arrow) were partially characterized.  
2.3.8.1. Characterization of anticoagulant protein with mass 7279 Da 
The protein with mass of 7279.66 ± 0.98 Da was purified from peak 2 indicated by 
blue arrow (Fig. 2.3, 2.18A,B). The dose-response effect of 7277 on FX activation by 
extrinsic tenase complex was examined and the IC50 value of 17.37 ± 1.91 nM was 
determined (Fig. 2.18c). We have not determined the amino acid sequence of this 
protein. 
2.3.8.2. Characterization of anticoagulant protein with mass 7438 Da 
[Note: The work on this protein was continued by Bhaskar Barnwal, a graduate 
student from my lab. The partial amino acid sequence was determined by both of us.]  
The peak 6 (red arrow) was sub-chromatographed to purify the anticoagulant protein 
with mass 7438.63 ± 1.7 Da (Fig. 2.3, 2.19A,B). The protein inhibited FX activation 
by extrinsic tenase complex with an IC50 value of 52.6 ± 3.7 nM (Fig. 2.19C).  The 
partial sequence of the native protein was determined through Edman degradation. 
Sequence comparison showed its high identity towards 3FTxs, especially to a 





2.3.8.3. Characterization of anticoagulant proteins from peak 10 
[Note: The partial amino acid sequence of proteins P10b and P10d were determined 
by me and Dr. Guna Shekhar, who continued with the characterization of these 
proteins] 
The peak 10 (Fig. 2.3) contained two major proteins 6770 Da and 6800 Da as 
determined by ESI-MS, so we went on to separate the proteins by cation exchange 
chromatography on a Shodex SP-825 column. The column was equilibrated with 25 
mM citrate buffer pH 5 and the proteins were eluted with 1M NaCl in 25 mM citrate 
buffer pH 5. Peak 10 was fractionated into four peaks (P10a, P10b, P10c and P10d) 
(Fig. 2.20A). Each peak was run on a C-18 reverse-phase column. All the four 
proteins showed similar elution times in RP-HPLC (Fig. 2.20B). The mass of the 
individual proteins were determined by ESI-MS. Proteins P10a and P10c differed in 1 
Da mass with P10a as 6771.10±0.028 Da and P10c as 6770.08±0.02 Da. Similarly, 
the proteins P10b and P10d also differed in 1 Da mass with P10b as 6801.31±0.05 Da 
and P10d as 6800.3±0.06 Da. The similar elution profile of the four proteins from 
peak 10 in RP-HPLC as well as the mass difference of 1 Da suggests that the four 
proteins might be isoforms. The peak 10 with all the four isoforms exhibited a dose-
dependent inhibition of FX activation by extrinsic tenase complex (IC50 = 1.11 ± 0.27 
µg/ml) (Fig. 2.20C), however the individual isoforms failed to exhibit any inhibition 
at concentration of 1 µM, suggesting a synergism among the isoforms for mediating 
anticoagulant property (data not shown). The partial amino acid sequence for all the 
four isoforms were determined and showed a difference of one residue. P10a, P10c 
and P10b, P10d differed in one residue at position 17 (D to N) explaining the 1 Da 
difference. Also, P10a, P10b and P10c, P10d differed in positions 10 and 33, 
explaining the 30 Da difference among them. This suggests that both proteins might 
 118 
 
be identical in sequence towards their C-terminal. The sequence alignment showed 
that the proteins shared similarity to other three-finger toxins especially the cytotoxins 












































































































Figure: 2.18. Characterization of the anticoagulant protein with mass 
7279 Da. A) The purification of anticoagulant protein with mass 7279 Da 
on RP-HPLC using a Jupiter C18 column (4.6 X 250 mm). B) The mass of 
the purified protein as determined by ESI-MS was found to be 7279.66 ± 
0.98 Da. C) The anticoagulant property of the protein as determined on FX 
activation by the extrinsic tenase complex. An IC50 value of 17.37 ± 1.91 
nM was obtained. The enzyme assays were done with n=3 and data 






























































            7439             RLCLSDYSIFSETIEICPEGHNYCFKKFPKGITRLPWVI   
            NTL2             RLCLSDYSIFSETIEICPDGHNFCFKKFPKGITRLPWVI      95 
            D2A              LLCLQKYSPGRETSQTCLAGENICFKKWKKGEKTSRXGC      43 
            Toxin 7          RKCLTKYSRDNESSKTCPSGQNVCFKKWEMGNSSEKNAK      38 
            MT1              LTCVTSKSIFGITTENCPDGQNLCFKKWYYIVPRYSDIT      38 



























Figure: 2.19. Characterization of the anticoagulant protein with mass 
7438 Da. A) The purification of anticoagulant protein with mass 7438 Da 
on RP-HPLC using a Jupiter C18 column (4.6 X 250 mm). B) The mass of 
the purified protein as determined by ESI-MS was found to be 7438.63 ± 
1.7 Da. C) The anticoagulant property of the protein as determined on FX 
activation by the extrinsic tenase complex. An IC50 value of 52.6 ± 3.7 nM 
was obtained. D) The partial amino acid sequence of 7438 as determined 
by Edman degradation. The conserved cysteine residues and identical 
residues are highlighted in black. For sequence comparison, the following 
sequences were used: neurotoxin like protein NTL2 from N. naja; short 
neurotoxin D2A from M. pyrrhocryptus; toxin 7 from B. flaviceps; 
muscarinic toxin 1 MT1 from D. angusticeps and muscarinic toxin like 
protein 2 MTLP 2 from N. kaouthia. The enzyme assays were done with 



















































































P10a            LKCHNKLVPFLSKTCPDGKNLCYKMSMQVTPMV 
P10b            LKCHNKLVPYLSKTCPDGKNLCYKMSMQVTPMI 
P10c            LKCHNKLVPFLSKTCPNGKNLCYKMSMQVTPMV 
P10d            LKCHNKLVPYLSKTCPNGKNLCYKMSMQVTPMI 
 
        P10a                LKCHNKLVPFLSKTCPDGKNLCYKMSMQVTPMV      
        Cytotoxin-3         LKCHNKLVPFLSKTCPDGKNLCYKMSMEVTPMI     94 
        Cytotoxin-1         LKCHNKLVPFLSKTCPEGKNLCYKMTMLKMPKI     79 
        Cytotoxin-2         LKCHNKVVPFLSKTCPEGKNLCYKMTLKKVPKI     73 


















Figure 2.20: Characterization of anticoagulant proteins from peak 10. 
A) Peak 10 was separated into four proteins denoted as P10a, P10b, P10c 
and P10d on cation-exchange chromatography. The proteins were eluted 
using 1M NaCl in 25 mM citric acid buffer, pH 5. B) Proteins in each peak 
from cation-exchange chromatography co-eluted together in RP-HPLC, 
suggesting them to be isoforms. C) The effect of peak 10 having the four 
isoforms as evaluated on FX activation by the extrinsic tenase complex. An 
IC50 value of 1.11 ± 0.27 µg/ml was obtained. D) Represents the partial 
sequence of peak 10 isoforms. P10a, P10c and P10b, P10d differ at 17
th
 
position (D to N) explaining the 1 Da difference among these isoforms. 
However P10a, P10b and P10c, P10d differ by 30 Da that can be explained 




 position. E) Partial sequence of P10a was 
compared with other cytotoxins. Comparisons were made with cytotoxin-3, 





Cardiovascular and cerebrovascular diseases resulting from unwanted clots are the 
major cause of death in developed countries (Mann et al., 2003; Gross and Weitz, 
2008). Anticoagulants prevent the formation of unwanted clots and hence death. Due 
to their non-specific mode of action, currently used anticoagulants like warfarins and 
heparins have limited therapeutic window (Nutescu, 2006; Fareed et al., 2008). Thus 
there is a need for novel anticoagulants that can target specific steps in the coagulation 
pathway. The extrinsic activation complex is crucial for the initiation of the blood 
coagulation cascade in response to a vascular injury (Hedner and Ezban, 2008; Ott, 
2011) and hence been identified as an important target for anticoagulation therapies. 
Over the years, several specific inhibitors to this complex have been characterized. 
These inhibitors are from two key sources- saliva/salivary gland extracts of 
hematophagous animals and snake venoms (Stark and James, 1996; Koh and Kini, 
2008). Though various snake venom proteins targeting the extrinsic activating 
complex have been characterized (Kini, 2006; Yamazaki and Morita, 2007), very little 
information is known about anticoagulant 3FTxs. Recently an anticoagulant 3FTx, 
hemextin from the venom of H. haemachatus was characterized. Hemextin targets the 
extrinsic activating complex, specifically FVIIa non-competitively with nanomolar 
affinity (Banerjee et al., 2005; Banerjee et al., 2007). In search of novel 
anticoagulants targeting the extrinsic activation complex, the crude venom of H. 
haemachatus was screened. Preliminary studies showed proteins in both peak 2 and 3 
of SEC prolonging the plasma clotting time (Fig. 2.2), indicating their anticoagulant 
properties. Peaks 2 and 3 contained proteins that mostly belong to phospholipase A2 
and 3FTx families, respectively (Joubert, 1975; Yang and King, 1980). Phospholipase 
A2 mediates their anticoagulant activity through enzymatic mechanisms. Since major 
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focus was given in characterizing the non-enzymatic anticoagulants, 3FTxs were 
purified from peak 3. Peak 3 on RP-HPLC revealed the presence of a number of 
anticoagulants targeting the extrinsic activation complex (Fig. 2.3). However, exactin 
was purified and characterized (peak marked with black arrow) because of the 
following reasons. Initial plasma clotting studies with all the peaks from RP-HPLC of 
peak 3 revealed that exactin peak (peak marked with black arrow) and peak 10 (peak 
marked with green arrow) prolonged the prothrombin time (>150s; n = 2) more 
significantly when compared to others. Moreover, exactin exhibited high inhibitiory 
potency towards FX activation by the extrinsic tenase complex when compared to 
peak 10 (Fig. 2.3).  
The complete amino acid sequence of exactin was determined by Edman degradation. 
The sequence alignment has revealed its high identity towards short neurotoxins (>58 
%). However, it shared low identity (<35 %) towards the well characterized short-
chain α-neurotoxins (like erabutoxin A, toxin-α, haditoxin, α-neurotoxin) and 
anticoagulant 3FTxs (like hemextin, siamextin and naniproin). Anticoagulant 3FTxs 
characterized to date are highly identical to cardiotoxins/cytotoxins. Thus exactin 
shared a unique sequence when compared to other 3FTxs. 
Inorder to delineate the anticoagulant site of exactin in the coagulation cascade, we 
used the ‘Dissection approach’ (Kini and Banerjee, 2005). Previously, this approach 
was used to understand the anticoagulation site of hemextin (Banerjee et al., 2005) 
and naniproin (Unpublished data). Hemextin, a FVIIa inhibitor prolonged the 
prothrombin time without affecting the Stypven time and thrombin time suggesting its 
target as the extrinsic activation complex while naniproin from N. nigricollis 
prolonged Stypven time more significantly when compared to APTT and prothrombin 
time. But thrombin time was not affected, suggesting its target as the prothrombinase 
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complex. Exactin like hemextin also prolonged the prothrombin time more 
significantly than APTT and Stypven time without affecting thrombin time, 
suggesting its target as the extrinsic activation complex. Inorder to validate the results 
with plasma clotting times, the effect of exactin towards the reconstituted extrinsic 
tenase complex, intrinsic tenase complex, prothrombinase complex and thrombin 
amidolytic activity was evaluated. Exactin exhibited high inhibitory potency towards 
FX activation by the extrinsic tenase complex (IC50=116.49 ± 3.28 nM) compared to 
FX activation by intrinsic tenase complex (>30-folds), PT activation by 
prothrombinase complex (>100-folds) and thrombin amidolytic activity (>1000-
folds).  The results thus confirm the anticoagulation site of exactin to be the extrinsic 
activation complex. 
Kinetic studies showed that exactin exhibits a mixed-type inhibition towards FX 
activation by extrinsic tenase complex, FVIIaPL and FVIIa/sTF. The affinity of the 
inhibitor towards the enzyme-substrate complex (FVIIa/TFPL/FX), Ki’ 30.62 ± 7.73 
nM) was 5-fold higher compared to the enzyme complex (FVIIa/TFPL), Ki 153.75 ± 
17.96 nM) suggesting its preference to [ES] complex. Though exactin inhibited FX 
activation by extrinsic tenase complex and FVIIaPL with equi-potency (116.49 ± 3.28 
nM versus 102.7 ± 11.71 nM), in the absence of TF Ki’ dropped 3-fold to 103 ± 13.49 
nM with a slight decrease in Ki of 184.25 ± 6.13 nM. Thus, exactin appears to bind to 
the complete complex better than FVIIa/FX complex. The 3-folds difference in 
affinity could be explained by the fact FX interacts with both TF as well as FVIIa on 
the membrane surface to form a perfect extrinsic activation complex for its efficient 
catalysis. These exosite interactions determine the affinity of FX towards the extrinsic 
tenase complex (Baugh et al., 2000). Even the macromolecular binding exosite on 
FVIIa is modulated by allosteric binding of TF (Ruf et al., 1992; Ruf et al., 1992; 
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Huang et al., 1996; Kirchhofer et al., 2000; Eigenbrot, 2002). However, the unaltered 
affinity to enzyme suggests that exactin can interact well with FVIIa even in the 
absence of its cofactor. The affinity of exactin was drastically reduced by >1000-folds 
for FX activation in the absence of phospholipids (Ki’, 295 ± 7.07 µM; Ki, 1250 ± 
56.6 µM), suggesting its preference towards membrane-bound complex. The 
importance of phospholipids in FX catalysis by extrinsic tenase complex is well 
studied (Bom and Bertina, 1990). It has been hypothesized that conformational 
alterations of factor X upon phospholipid binding change susceptibility of the Arg-Ile 
bond to proteolytic activation, presumably by influencing recognition and peptide 
bond hydrolysis by the tenase complex (Ruf et al., 1991). These conformational 
changes on FX upon phospholipid binding could be compared with that of 
prothrombin binding to the membrane surface via its Gla domain. FXa in the absence 




 to form prethrombin 2 as an 
intermediate. However, in the presence of cofactor FVa and phospholipids, FXa 




 of prothrombin to form meizothrombin as 
intermediate. This reaction required Gla domain as Gla domainless prothrombin upon 
cleavage by FXa produced prethrombin 2 (Malhotra et al., 1985). The drastic drop in 
Ki’ and Ki for exactin in the absence of phospholipids could be explained by the fact 
that substrate-membrane interaction is important for the efficient catalysis of human 
FX by the extrinsic tenase complex. Proper anchorage of coagulation factors FVIIa 
and FX on to the membrane surface via Gla domain enable in the efficient formation 
of the extrinsic activation complex (Nelsestuen et al., 1978; Krishnaswamy et al., 
1992). Also FRET analysis has shown that once bound to the membrane surface, the 
active site of both FVIIa and FXa are oriented perpendicular above the membrane 
surface (Husten et al., 1987; Morrissey, 2001). Exactin however, demonstrated poor 
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inhibition towards the amidolytic activities of FVIIa and FXa (Fig. 2.9B), suggesting 
that it does not target the active site of the coagulation factors. Moreover, the results 
support the fact that exactin preferably inhibits the proteolytic activation of the 
macromolecular substrate FX. We have also determined the kinetic parameters (KM 
and Kcat) for the inhibition of FX activation in the presence of exactin. The KM and 
Kcat for FX activation by extrinsic tenase complex, FVIIaPL and FVIIa/sTF in the 
absence of exactin were obtained as 14.57 ± 0.87 nM; 1.7 ± 0.017s
-1
, 36.56 ± 2.76 
nM; 0.0558 ± 0.0046 s
-1
, 1.03 ± 0.089 µM; 0.0017± 6.13 E-05 s
-1
, respectively. These 
values were significant when compared to those determined previously (Bom and 
Bertina, 1990; Soejima et al., 2002; Chen et al., 2004; Waters et al., 2006). However, 
the KM value calculated (14 nM) for FX activation by extrinsic tenase complex was 4-
5 folds lower compared to that reported earlier. Probable reason for this difference 
could be attribuited to the tissue factor used. In all the experiments with extrinsic 
tenase complex, human recombinant tissue factor Innovin was used. As per the 
suppliers manual, Innovin contained PE in undetermined ratios apart from PC and PS. 
The effect of PE in enhancing FVIIa/TF proteolytic activity has been studied 
(Neuenschwander et al., 1995; Tavoosi et al., 2011). The kinetic analysis has shown a 
decrease in KM and Kcat with increase in inhibitor concentration (Table 2.1, 2.2, 2.3), 
characteristic of mixed-type inhibition. This has also been observed with nitrophorin 
2, a tick inhibitor that specifically inhibits intrinsic activation complex (Zhang et al., 
1998). It could be thus inferred that binding of exactin to the extrinsic activation 
complex, increases the affinity of FX towards the tenase complex, however with a 
reduced catalysis. The kinetic analysis has thus given a better understanding of the 
mechanism of inhibition of the extrinsic activation complex by exactin. 
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 bond resulting in the 
release of a 52 residue activation peptide. This activation is catalyzed by the extrinsic 
tenase complex, intrinsic tenase complex and the snake veom FX activator RVV-X 
(Fujikawa et al., 1974; Bom and Bertina, 1990; Duffy and Lollar, 1992; Takeya et al., 
1992; Siigur and Siigur, 2006). Exactin exhibited high specificity towards extrinsic 
tenase (IC50 - 116 nM) when compared to intrinsic tenase complex (IC50 - 4.05 ± 0.32 
µM) and RVV-X (IC50 - 6.1 ± 2.9 µM) in inhibiting FX activation. Kinetic analysis of 
FX activation by intrinsic tenase and RVV-X in the presence of exactin was also 
studied. Exactin non-competitively inhibited the proteolytic activation of FX by 
intrinsic tenase complex and RVV-X (Ki of 1.67 ± 0.35 µM and 2.79 ± 0.29 µM, 
respectively). The kinetic parameters, KM and Kcat were determined and were 
significant when compared to that reported previously (Van Dieijen et al., 1981; 
Baugh and Krishnaswamy, 1996; Gilbert and Arena, 1996; Wilkinson et al., 2002, 
Table 2.4, Table 2.5). This implies that exactin interferes with the proteolysis of FX 
as both intrinsic tenase and RVV-X, like extrinsic tenase activates FX by a similar 
activation mechanism. Also FVIIa and FIXa share a serine protease domain while 
RVV-X has got a metalloprotease domain (Fujikawa et al., 1974; Bom and Bertina, 
1990; Duffy and Lollar, 1992; Takeya et al., 1992; Siigur and Siigur, 2010). Thus 
exactin exhibits high specificity in inhibiting FX activation specifically by the 
extrinsic tenase complex. 
The extrinsic tenase complex can proteolytically activate both the macromolecular 
substrates FX and FIX (Fujikawa et al., 1974; Zӧgg and Brandstetter, 2011). Though 
the mechanisms of activation are different, FX represents a better macromolecular 
substrate when compared to FIX as the former has a higher affinity to phospholipid 
membranes (Kd for FX, 0.25 µM and Kd for FIX, 2 µM). Also the rate of activation of 
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FX is faster when compared to FIX (Fujikawa et al., 1974; Nelsestuen et al., 1978; 
Zur and Nemerson, 1980; Warn-Cramer and Bajaj, 1986; Komiyama et al., 1990; 
Zӧgg and Brandstetter, 2011). Exactin exhibited >200-folds inhibition to FX 
activation (IC50, 116.49 ± 3.28 nM) when compared to FIX activation (IC50, 29.66 ± 
5.27 µM). Exactin exhibited a mixed-type inhibition ( Ki’, 38.66 ± 10.27 µM; Ki, 
128.6 ± 12.54 µM) towards FIX activation as observed from a decrease in KM and 
Kcat with increase in inhibitor concentration (Table 2.6). The kinetic parameters KM 
and Kcat determined for FIX activation by extrinsic tenase complex were significant 
when compared to that reported previously (Zur and Nemerson, 1980; Warn-Cramer 
and Bajaj, 1986). Thus exactin specifically inhibits activation of FX compared to FIX, 
though both FX and FIX serves as the macromolecular substrate for the extrinsic 
tenase complex. 
A mechanism was proposed to explain the inhibition of FX activation by exactin (Fig. 
2.21). The kinetic analysis suggests that exactin specifically inhibits FX activation by 
the extrinsic tenase, preferably binding to FX (based on the non-competitive mode of 
inhibition of FX activation by intrinsic tenase complex and RVV-X), hence 
preventing its proteolytic cleavage. The affinity of exactin towards enzyme remains 
unaltered in the absence of TF, suggesting that exactin can interact well with FVIIa 
but not the active site (as per the results from FVIIa amidolytic activity). The removal 
of PL has drastically reduced the inhibition which can be attributed to the fact that PL 
helps in organizing the extrinsic activation complex for proper proteolysis (Tavoosi et 
al., 2011; Morrissey et al., 2011). Thus exactin prefers the entire enzyme-substrate 
complex (FVIIa/TFPL/FX) to exhibit its inhibition. To date, the only functionally 
characterized classical molecules targeting the extrinsic activation complex 
(FVIIa/TFPL/FX) are tissue factor pathway inhibitor TFPI (Girard et al., 1990; 
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Hamamoto et al., 1993), ixolaris (Francischetti et al., 2002; Monteiro et al., 2008), 
NAPc2 (Bergum et al., 2001; Vlasuk and Rote, 2002) and hemextin (Bannerjee et al., 
2005). TFPI, ixolaris and NAPc2 inhibits the extrinsic activation complex with 
picomolar affinity (for details see Introduction) by binding to both FX(a) and FVIIa, 
thus affecting their amidolytic activities. Moreover, ixolaris and NAPc2 bind to the 
heparin binding exosite on FX(a). Hemextin on the other hand inhibits FVIIa alone 
without binding to FX (for details see Introduction). Exactin differs from these 
classical inhibitors in that it does not affect the amidolytic activities of either FVIIa or 
FXa. However, exactin binds to both FX and FVIIa (as exactin exhibits mixed-type 
inhibition with two different affinities to [ES] complex and E) and is highly specific 
in inhibiting FX activation by the extrinsic tenase complex. Currently, we do not have 
any information regarding the binding site of exactin on FX and FVIIa. Future 
experiments will thus focus on elucidating the binding site of exactin on the extrinsic 
activation complex.  
Apart from exactin, we have also partially characterized other anticoagulants from the 
same venom. The anticoagulant protein with mass 7438 Da had a partial sequence 
homologous with neurotoxin like proteins and muscarinic toxins. It would be 
interesting to understand their anticoagulant mechanism as both exactin and 7438 
were less identical. Similarly, peak 10 isoforms can also be an interesting target for 
anticoagulation studies, as our preliminary results suggest that there could be a 
synergism among the isoforms for their anticoagulant activity. The individual 
isoforms were not active at the highest possible concentration used (1 µM); however 
the peak 10 having the four isoforms exhibited potent inhibition towards FX 







































            Figure: 2.21: Proposed inhibitory mechanism of exactin. A) 
Proteolytic activation of the macromolecular substrate FX by 





Schematic representation of the extrinsic activation complex 
along with the top view is shown B) Exactin (represented as I) 
binds to the full extrinsic activation complex there by 
significantly reducing FX proteolysis. C) The removal of TF 
from the extrinsic activation complex however, does not alter 
the binding affinity of exactin and the inhibitor is able to inhibit 
FX proteolysis significantly. D) The removal of phospholipids 
from the extrinsic activation complex drastically reduced 
(>1000-folds) the inhibition of FX proteolysis by exactin, 









To summarize the results of this chapter, we have isolated, purified and determined 
the mechanism of inhibition of exactin, a novel 3FTx from the venom of H. 
haemachatus. Though the initial screening revealed the presence of a large number of 
inhibitors targeting the extrinsic activation complex, we purified and characterized 
exactin due to its high potency. Sequence alignment studies showed its identity to 
short neurotoxins. The ‘Dissection approach’ has assigned its target as ‘extrinsic 
activation complex’ (FVIIa/TFPL/FX). Further detailed studies, involving the kinetics 
of inhibition as well as effect on macromolecular complexes (both enzyme and 
substrate), has shown that exactin specifically inhibits FX activation by extrinsic 
tenase complex (FVIIa/TFPL). Based on the results, a mechanism was proposed to 
explain the inhibitory mechanism of exactin. Exactin inhibits FX activation, by 
preferably binding to the macromolecular substrate FX and preventing its catalysis by 
the extrinsic tenase complex. Even the removal of TF does not alter the inhibition 
significantly. However, in the absence of PL, the inhibition of FX activation dropped 
drastically, suggesting that exactin prefers the entire enzyme-substrate complex 
(FVIIa/TFPL/FX) to exhibit its inhibition.  The binding site of exactin on FVIIa and 
FX has yet to be elucidated. We have also partially characterized other anticoagulants. 
Currently, we are looking into their structure-function studies. Thus to conclude, we 
have successfully purified and characterized a novel 3FTx with a unique sequence and 
a unique mechanism of action when compared to the classical exogenous inhibitors of 



































Snake venom toxins are known to interfere with cholinergic transmission (Chang and 
Lee, 1963; Karlsson et al., 1966; Karlsson, 1979) in the central and peripheral 
nervous systems and can be subdivided into three major classes - muscarinic toxins, 
fasciculins and neurotoxins. Since this thesis deals with the neurotoxic effects of 
exactin, a brief account of neurotoxic 3FTx has been given. 
3.1.1. Snake venom neurotoxins 
Snakes use their venom neurotoxins to paralyze the prey so that they can feed the prey 
more effectively. When bitten by the snake, these neurotoxins cause rapid paralysis of 
the voluntary muscles resulting in lack of movement and respiratory paralysis and 
finally death of the prey. Snake venom neurotoxins can be classified as either 
postsynaptic or presynaptic, depending on their site of action. Most of the 
postsynaptic neurotoxins fall into the group of 3FTxs also called  as ‘curaremimetic 
toxins' due to their similarity in action to the arrow poison curare, a competitive 
nicotinic acetylcholine receptor antagonist (Endo & Tamiya, 1991). Based on the 
target receptors as well as primary structures, postsynaptic neurotoxins can be 
classified as - curaremimetic or α-neurotoxins, κ-neurotoxins and non-conventional 
neurotoxins. The α-neurotoxins can be subdivided into short-chain α-neurotoxins (60-
62 amino acid residues with four conserved disulfide bridges) and long-chain α-
neurotoxins (66-74 amino acid residues with four conserved disulfide bonds with an 
additional disulfide bond in the tip of loop II) (Endo and Tamiya, 1991; Servent and 
Menez 2001). Both short-chain and long-chain α-neurotoxins target muscle (αβγδ or 
α1subtype) nAChRs (Nirthanan and Gwee, 2004; Tsetlin, 1999; Changeux, 1990). 
Apart from the structural differences, both short and long-chain neurotoxins differs 
functionally, mainly in the kinetics of association and dissociation with skeletal 
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muscle nicotinic acetylcholine receptors (Chicheportiche et al., 1975; Tsetlin, 1999). 
Also long-chain neurotoxins but not short-chain neurotoxins targets the α7- nAChRs 
associated with neurotransmission in the brain (Servent et al., 1997; Servent et al., 
2000). 
κ-neurotoxins are homodimeric complexes of 3FTxs (Dewan et al., 1994). They are 
structurally similar to long chain α-neurotoxins with five disulfide bonds (the 
additional one is in the tip of loop II) but have a shorter C-terminal tail like the short 
chain α-neurotoxins, and intermediate number of (66) amino acid residues (Grant and 
Chiappinelli 1985; Fiordalisi et al., 1994). The κ-bungarotoxin (Bungarus 
multicinctus), a member of this group show specificity for other neuronal subtypes, 
α3β2- and α4β2-nAChRs (Grant and Chiappinelli, 1985; Wolf et al., 1988).  
Non-conventional 3FTxs are characterized by the presence of 62-68 amino acid 
residues and a fifth disulfide bond in loop I compared to long chain α-neurotoxins 
where the fifth disulfide linkage is present in the second loop. These toxins are also 
referred as ‘weak toxins’ based on their low in vivo toxicity (LD50 ~ 5–80 mg/kg) 
when compared to the highly lethal α-neurotoxins (LD50 ~0.04–0.3 mg/kg) (Utkin et 
al., 2001). However, candoxin isolated from the venom of Bungarus candidus 
(Nirthanan et al., 2002) are exceptional to this convention in that candoxin produced a 
potent reversible neuromuscular blockade and  also interacted with α7-nAChRs with 
nano molar affinity (Nirthanan et al., 2002).  
To understand the usefulness of exactin as an anticoagulant lead, we studied its 
toxicity on animals. This chapter thus covers the in vivo and ex vivo neurotoxicity 
studies of exactin. [Note: the experiments done for this chapter were with the help of 




3.2. Material and Methods 
3.2.1. Materials 
Lyophilized H. haemachatus crude venom was purchased from South African Venom 
Suppliers (Louis Trichardt, South Africa) and exactin was purified as described in 
chapter 2. The drugs used for pharmacological studies - acetylcholine chloride and 
carbamylcholine chloride (carbachol) were purchased from Sigma-Aldrich (Missouri, 
USA). α-bungarotoxin from B. multicinctus was also purchased from Sigma-Aldrich. 
Erabutoxin b was purchased from Latoxan (Rue Léon Blum, France). Potassium 
chloride (KCl) was from Merck KGa (Darmstadt, Germany). All other chemicals and 
reagents used were of the highest purity. The stock solutions of the drugs and exactin 
were prepared fresh by dissolving in deionized water.  
3.2.2. Animals 
Animals (Swiss albino mice) acquired from the National University of Singapore 
Laboratory Animal Center were acclimatized to the Department Animal Holding Unit 
for at least 3 days before the experiments. Food and water were provided ad libitum in 
a light controlled room (12-h light/dark cycle, light on at 7:00 a.m.) at 23 °C and 60% 
relative humidity. Domestic chicks were purchased from Chew’s Agricultural Farm, 
Singapore, and delivered on the day of experimentation. Animals were sacrificed by 
exposure to 100% carbon dioxide. All experiments were conducted according to the 
Protocol (021/07a) approved by the Institutional Animal Care and Use Committee of 
the National University of Singapore. 
3.2.3. In vivo toxicity studies 
Exactin in 0.9% saline was injected intraperitoneally (i.p) using a 27-gauge 0.5-inch 
needle (BD Biosciences) into male Swiss albino mice (32 ± 2 g) at doses of 10 and 
100 mg/kg (n=2). The symptoms were observed and the time it took to kill the mice 
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was also noted. The control group was injected with 0.9% saline. Once the death was 
confirmed, postmortem examinations were conducted on all animals. 
3.2.4. Ex vivo organ bath studies 
The effect of exactin on chick biventer cervicis muscle (CBCM) preparations were 
carried out on a conventional organ bath (6 ml) containing Krebs solution [(in mM): 
118 NaCl, 4.8 KCl, 1.2 KH2PO4, 2.5 CaCl2, 25 NaHCO3, 2.4 MgSO4, and 11 D-(+) 
glucose], pH 7.4 at 37 ºC (Nirthanan et al., 2002; Pawlak et al., 2009). The solution 
was continuously aerated with carbogen (5% CO2 in oxygen). The resting tension of 
the tissues maintained at 0.5-1.5 g were allowed to equilibrate for 30–45 min. 
Electrical field stimulation was provided through platinum ring electrodes using a 
Grass stimulator S88 (Grass Instruments, West Warwick, RI). The magnitude of the 
contractile response was measured in gram tension. The CBCM nerve-skeletal muscle 
preparation (Ginsborg and Warriner, 1960) isolated from 6-day old chicks were 
mounted in the organ bath chamber under similar experimental conditions as 
described previously (Ginsborg and Warriner, 1960; Nirthanan et al., 2002). The 
effect of exactin (0.1 µM to 30 µM) on nerve-evoked twitch responses of the CBCM 
were examined. A dose-response curve for exactin’s effect on neuromuscular 
blockade after 15 min of exposure was derived  by continuously recording the data on 
a PowerLab/Chart 5 data acquisition system via a force displacement transducer 
(Model MLT0201) (AD Instruments, Bella Vista NSW, Australia). In separate 
experiments, the recovery from complete neuromuscular blockade was assessed by 
washing out the protein with Krebs solution at regular cycles of 30 s wash followed 






3.3.1. Neurotoxicity of exactin 
3.3.1.1. In vivo toxicity studies 
Exactin (10 and 100 mg/kg) were injected i.p. to study the in vivo toxicity. At 10 
mg/kg, after 10 min the mice were stretching their hind limbs and were immobile. 
However, it regained its normal activity after 30 min. At 100 mg/kg, immediately 
after IP injection, the mice showed typical symptoms of peripheral neurotoxicity such 
as hind limb paralysis, immobilization and labored breathing (Laothong and Sitprija, 
2001). The mice died within 35 min, presumably due to respiratory paralysis. 
Postmortem examination showed no significant changes, particularly hemorrhage or 
internal bleeding, were observed in their internal organs.   
3.3.1.2. Ex vivo organ bath studies 
To evaluate the observed peripheral neurotoxic symptoms, we studied the effect of 
exactin (0.1 to 30 µM) on neuromuscular junctions in CBCM preparations. Exactin 
(10 μM) produced a time-dependent neuromuscular blockage (Fig. 3.1A). It also 
inhibited contractile responses of the exogenously applied nicotinic agonists (ACh 
and CCh), whereas responses to exogenous KCl and twitches evoked by direct muscle 
stimulation were not inhibited. These results indicated that exactin induces a 
postsynaptic neuromuscular blockage but lacks direct myotoxicity. Intermittent 
washing resulted 80% recovery of the twitch height in 8.5 min (Fig. 3.1B) denoting 
that neuromuscular block by exactin is reversible. Exactin induces a dose-dependent 
block with an EC50 value of 4.4 µM.  When compared to erabutoxin b and α-






















Figure 3.1: Effect of exactin on CBCM preparations. A) A 
segment of tracing showing the effect of 10 µM exactin on the 
twitch response of CBCM elicited by nerve stimulation and 
exogenously supplied acetylcholine (ACh), carbachol (CCh) and 
potassium chloride (KCl). The vertical bar represents the 
magnitude of twitch response in gram tension and the horizontal 
bar depicts the time in minute. B) Reversibility of the nerve 
evoked twitch response blockade produced by exactin in CBCM. 
The segment of tracing shows complete blockade of nerve evoked 
twitch response by 10µM exactin. Once complete blockade is 
achieved, exactin is removed from the bath chamber by extensive 
washing (at regular cycles of 30 s wash followed by 1 min 
interval over a period of 30 min) with Krebs solution. The vertical 
bar represents the magnitude of twitch response in gram tension 
and the horizontal bar depicts the time in minute. All the 

















Exactin      LECYQK-----SKVVTCQPEQKFCYSDTTMFFPNHPVYLSGCTFSCTEEGN----RRCCTTDKCNR  
Toxin-α      LECHNQQSSQPPTTKTC-PGETNCYKKVWRDH-RGTIIERGCG--CPTVKP-GIKLNCCTTDKCNN  33 
Haditoxin    TKCYNHQSTTPETTEICPDSGYFCYKSSWIDG-REGRIERGCTFTCPELTPNGKYVYCCRRDKCNQ  33 
α-neurotoxin RICYNHQSTTRATTKSC--EENSCYKKYWRDH-RGTIIERGCG--CPKVKP-GVGIHCCQSDKCNY  26  
Erabutoxin A RICFNHQSSQPQTTKTCSPGESSCYNKQWSDF-RGTIIERGCG--CPTVKP-GIKLSCCESEVCNN  26 
Erabutoxin B RICFNHQSSQPQTTKTCSPGESSCYHKQWSDF-RGTIIERGCG--CPTVKP-GIKLSCCESEVCNN  26 
 
Figure 3.3: Sequence comparison of exactin to the well characterized short-chain 
α-neurotoxins. The conserved eight cysteine residues are highlighted in black. The 
key functional invariant residues responsible for neurotoxicity in erabutoxin, based on 
mutational studies are highlighted in red. The comparison was made with the 
following sequences: Toxin-α from N. nigricollis; haditoxin from O. hannah, α-
neurotoxin from D. polylepis polylepis; erabutoxin a and erabutoxin b from L. 
semifasciata. 
 





















Figure 3.2: Dose-response effect of exactin on CBCM. The 
EC50 value for exactin ( ) on CBCM at T=15 min was 
determined to be as 4.4 µM. It was compared to erabutoxin b 
( ) (EC50 = 80 nM) a short-chain α-neurotoxin and α-
bungarotoxin ( ) (EC50 = 25 nM), a long-chain neurotoxin. 




Anticoagulant 3FTxs characterized to date belongs to cardiotoxins/cytotoxin group 
(Banerjee et al., 2005; naniproin, siamextin [unpublished observations]). 
Interestingly, exactin showed only <35% identity to this group (Fig. 2.6B). Exactin 
shared highest identity to toxin CM-1b, CM-2a and CM-3. However, CM-1b from 
Hemachatus (Joubert and Taljaard, 1979) and CM-2a and CM-3 from Naja haje 
annulifera (Joubert, 1977) venom were not functionally characterized. Exactin also 
exhibited sequence identity (>58%) to many short-neurotoxins from O. hannah (Fig. 
2.6A). Most of them were not functionally characterized (He et al., 2004; Li et al., 
2006) except for the toxin OH9-1. OH9-1 was found to be a potent irreversible 
postsynaptic neurotoxin on CBCM preparations. It exhibited EC50 value of 88 nM, 4 
folds lower to α-bungarotoxin (Chang et al., 2002).  
To evaluate the biological effect and hence its usefulness as a lead molecule, we 
studied the in vivo toxicity of exactin in mice. Typical symptoms of peripheral 
neurotoxicity such as hind limb paralysis, immobilization and labored breathing 
(Laothong and Sitprija, 2001) were observed in mice administered with high dose of 
exactin (100mg/kg) suggesting its biological role in affecting the neurotransmission. 
These observations were also similar to that found with curare-mimetic neurotoxins 
(Chang, 1979). Postmortem analysis of the toxin administered mice revealed the 
absence of hemorrhage or bleeding of the internal organs, suggesting that exactin 
might not have any cytotoxic effects. This is also supported by the fact that exactin 
exhibited <35 % sequence identity to cytotoxins (Fig. 2.6B). We then evaluated the 
effect of exactin on neuromuscular junction using CBCM preparations. Exactin 
exhibited a reversible postsynaptic blockade of neuromuscular junction with an EC50 
value of 4.4 µM. However compared to erabutoxin b, a short-chain neurotoxin and α-
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bungarotoxin, a long-chain neurotoxin, the potency of exactin was 47 and 176 folds 
lower (Fig. 3.2). Also compared to OH9-1, exactin was found to be 50 fold less potent 
and readily reversible on neuromuscular blockade as derived from CBCM 
experiments. (Chang et al., 2002). The site directed mutagenesis studies have revealed 
the presence of many functional invariant residues in short-chain neurotoxins and 
long chain-neurotoxins towards the muscle type receptor (αβγδ) (Pillet et al., 1993; 
Trémeau et al., 1995, Fruchart-Gaillard et al., 2002; Dellisanti et al., 2007). The 
crucial residues for α-neurotoxins to bind to muscle (αβγδ) nAChRs are Lys-27, Trp-
29, Asp-31, Phe-32, Arg-33, and Lys-47. Apart from these, residues His-6, Gln-7, 
Ser-8, Ser-9, and Gln-10 in loop I; Tyr-25, Gly-34, Ile-36, and Glu-38 in loop II and 
Lys-47 in loop III of short-chain α-neurotoxins are also involved in the recognition of 
the receptors (Teixeira-Clerc et al., 2002). Arg-36 is a muscle subtype-specific 
determinant residue for long chain neurotoxins like α-bungarotoxin. However, exactin 
lacks all the functional invariant residues, explaining its low neurotoxicity. Morever, 
exactin also shared low identity towards the well characterized short-chain α-
neurotoxins (<35 % identity) (Fig. 3.3). Inorder to determine the affinity of exactin 
towards the muscle (αβγδ) nAChRs, we have collaborated with Prof. Daniel Bertrand 
of HiQSCREEN Sàrl, Geneva, Switzerland. We are yet to study the binding affinity 










To summarize the results of this chapter, we have studied the neurotoxic properties of 
exactin. Exactin is a highly potent anticoagulant towards the extrinsic activation 
complex. However, we need to understand its toxicity in animals for future 
therapeutic purposes. Our toxicity studies (in vivo and ex vivo) have shown that 
exactin exhibited a weak neurotoxicity in both mice and chick preparations. Though 
exactin shared homology with neurotoxins, compared to the well characterized short-
chain α-neurotoxins it was less potent. Thus we conclude that exactin is a novel three-
finger toxin with dual function; a potent and specific anticoagulant effect on the FX 














































In our previous studies (chapter 2), we have shown that exactin is a novel 3FTx 
having a unique amino acid sequence. It exhibited low sequence identity (<35%) 
towards anticoagulant 3FTxs (Fig. 2.6B) as well as the well characterized short-chain 
α-neurotoxins (Fig. 3.3). The CD profile showed the presence of predominant β-sheet 
structure. Apart from this, exactin also exhibited weak neuromuscular blockade (EC50 
of 4.4 µM compared to 80 nM of erabutoxin b) on the CBCM preparations. There was 
a 47 folds difference in the potency when compared with erabutoxin b though exactin 
lacks all the functionally invariant residues. Moreover, our kinetic studies have shown 
that exactin is a potent inhibitor of FX activation. Thus exactin is characterized by its 
dual role in anticoagulation and neurotoxicity. This makes it an important candidate 
for structure-function studies for which it is necessary to deduce the structure of 
exactin.  
X-ray crystallography was employed to determine the three-dimensional structure of 
exactin. This is based on the fact that electrons in the atoms forming the crystal can 
diffract X-rays and hence produce a particular diffraction pattern. A three-
dimensional electron density map of the molecule can thus be created from the 
diffraction pattern. Protein crystallization marks the most important part of protein 
crystallography studies. It is impossible to carry out any crystallographic structural 
studies without perfect protein crystals. The aim of protein crystallization is thus to 
produce well-ordered protein mono-crystals large enough to obtain a good quality 
diffraction data. Keeping this in mind, the crystallization screening of exactin was 
started to identify the condition which can generate crystals. The initial crystals 
obtained can be further optimized to yield diffraction quality crystals. In general, this 
chapter deals with the crystallization of exactin. We have optimized the crystallization 
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condition for exactin, in which we got good quality diffracting crystals. [Note: the 
crystallization of exactin was done in collaboration with Prof. Sivaramans’s lab. Mr. 
Thangavelu and Dr. Jobichen have helped me with diffraction of the exactin crystals 
























4.2. Materials and Methods 
4.2.1. Materials 
Exactin was purified from Hemachatus crude venom as described in chapter 2. All the 
crystallization screens (Hampton), crystallization trays, cover slips and grease were 
purchased from Hampton Research (CA, USA). 
4.2.2. Crystallization of exactin 
Crystallization conditions for exactin were screened with Hampton research screens 
(Crystal screen 1 HR2-110, Crystal screen 2 HR2-112 and SaltRx HR2-108) using a 
hanging-drop vapour-diffusion method. The lyophilized protein was dissolved in 10 
mM Tris-HCl buffer pH8.5. Crystallization experiments were carried out with 5 
mg/ml, 10 mg/ml, 20 mg/ml 50 mg/ml and 100 mg/ml concentrations of exactin. The 
drops were prepared by mixing equal volumes of (1 µl) of protein and crystallization 
solutions. In each well, 500 µl of reservoir solution (crystallization solution) was 
placed. The plates were set at 25 ºC, 16 ºC and 4ºC. The crystals once got were 
subjected for optimization to generate diffraction quality crystals. For X-ray 
diffraction data collection, the crystals were briefly soaked in reservoir solution 
supplemented with various cryoprotectants like 10% glycerol, 70% sucrose, 15% 
inositol, 2-propanol, PEG-400 and propylene glycol. Once data collected, the crystals 
were flash-freezed in liquid nitrogen for future synchrotron studies. 
4.2.3. X-ray diffraction and data collection 
The crystals were mounted on a nylon cryo-loop and frozen in liquid nitrogen stream. 
Diffraction up to 2.7 Å was obtained using a CCD detector mounted on a Bruker V8 
rotating anode generator (Bruker AXS, WI, USA). The complete data set collected 





4.3.1. Crystallization of exactin 
In all the Hampton screens used, crystals were produced at 4ºC only in a single 
condition of crystal screen HR2-112 (condition 17: 0.1 M sodium citrate tribasic 
dehydrate pH 5.6, 35% tert-butanol). We have tried crystallization with various 
exactin concentrations. However, crystals were obtained only at 100 mg/ml 
concentration. The crystals obtained in this condition were optimized for better 
diffraction quality by preparing grid screens of varying concentration of tert-butanol 
(26% to 32%). Through these optimizations, diffracting quality crystals were obtained 
in the condition, 0.1 M sodium citrate tribasic dehydrate pH 5.6, 29% tert-butanol 
(Fig. 4.1A). The crystals diffracted up to 2.7 Å (Fig. 4.1B). The diffraction data was 
indexed and scaled using HKL2000.  The crystals belonged to the C222 space group 
(orthorhombic crystal system) (Table 4.1). However, ice rings were observed in the 
diffraction pattern, even with the various cryoprotectants used. The data obtained was 
used to solve the structure of exactin using molecular replacement method. For this 
muscarinic toxin 2 isolated from D. angusticeps was used as a search model (pdb 
code 1FF4; sequence identity – 33%). There were 4 molecules in the asymmetric unit 






























Figure 4.1: Crystallization of exactin. A) The diffraction 
quality crystals of exactin were obtained in 0.1 M sodium 
citrate tribasic dehydrate pH 5.6, 29% tert-butanol. B) The 
diffraction pattern of exactin collected on a Bruker V8 









    Table 4.1: Crystallization parameters 
Data set  
Cell parameters and space group a=45.14, b=89.44, c=133.86 
α=β=γ =90º 
C222 
Resolution range (Å) 50 to 2.7  
Wavelength (Å) 1.5418 
Observed reflections >1σ 94907 
Unique reflections 7754 
Completeness (%) 99.6 (100) 
Overall (I/σI) 7.3 
Rsym
a












Even though very good diffracting quality crystals were, attempts to solve the 
structure using the molecular replacement was not successful. Various programs like 
Phaser and Molrep using the 33% identical homolog were used to obtain the phases. 
The data was subjected to twinning analysis and it showed the presence of twinning. 
This might be one reason for the failure of molecular replacement programs. Further 
crystallization trials have to be carried out to crystallize the protein in a different form 
so that an untwined data can be obtained. Another aspect might be the low sequence 
identity (33%) of the model used for molecular replacement with the protein of 
interest. Even with some small differences in the structure between the model and 
target protein, the molecular replacement programs will not be able to get a correct 
solution.  
The classical way to overcome this issue is going for heavy atom phasing, like MIR, 
SAD or MAD. But in this case the protein is purified from a native source which 
makes it difficult to carry out the heavy atom labelling. Only option available is 
soaking of the protein crystal with heavy atom like, Au, Hg etc. For soaking 
experiments there is a need to generate many crystals that can withstand the soaking 
condition. In this case the crystals obtained are in volatile conditions. The crystals 
degraded very fast in room temperature, making it very difficult for soaking 
experiments. Currently, attempts are made to crystallize the protein in other screening 
conditions which will enable heavy metal soaking and finally the elucidation of the 






To summarize this chapter, we attempted with crystallization of exactin. We got the 
crystals for exactin at high protein concentrations (100 mg/ml). Moreover, exactin 
crystallized in only one crystallization condition during the screening process. The 
crystals were optimized through grid screening. The diffraction quality crystals were 
taken to the in house x ray machine to collect data. However, we could not succeed in 
solving the structure of exactin through molecular replacement as it exhibited 
problems with twinning. Currently, we are optimizing more crystallization conditions 































Chapter 5  

































The thesis deals with the mechanism of a novel anticoagulant protein from the venom 
of Hemachatus haemachatus. Since the crude venom contained proteins of various 
molecular masses, SEC was used as an initial step of purification. The crude venom 
was separated into five peaks; with peak 2 and 3 exhibiting anticoagulant activity 
based on the prolongation of prothrombin time. Since peak 3 was comprised of 
3FTxs, it was separated on a RP-HPLC column and the effect of RP-HPLC fractions 
on FX activation by extrinsic tenase complex was evaluated. A large number of 
anticoagulants targeting the extrinsic activation complex were identified. However, 
exactin was purified and characterized further, as previously it was shown that exactin 
prolongs the prothrombin time much significantly when compared to others. Apart 
from exactin, a few other anticoagulants were also partially characterized. Currently 
their inhibitory mechanism is under investigation. The anticoagulant protein, exactin 
was purified to homogeneity and its mass determined as 6621 Da. The complete 
amino acid sequence of exactin was determined and was found to be unique because 
of its highest identity to short-neurotoxins. However, it exhibited least identity to the 
well characterized classical short-chain α-neurotoxins and anticoagulant cytotoxins. 
The ‘Dissection approach’ assigned the anticoagulant target of exactin to extrinsic 
activation complex, which was further validated through evaluating the effect of 
exactin to reconstituted blood coagulation complexes. Inorder to understand the 
mechanism of inhibition, the effect of exactin on the extrinsic activation complex was 
evaluated by sequentially removing each component of the complex. Removal of TF 
however, did not alter the IC50 value (102.70 ± 11.71 nM), but there was a >1000- 
folds decrease in the exactin inhibition, upon removal of PL. This was further studied 
with enzyme kinetics where exactin exhibited a mixed-type inhibition. However, 
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exactin inhibited FX activation by the extrinsic tenase complex and FVIIaPL with 
nanomolar affinities compared to that in the absence of PL (in the absence of PL the 
affinity towards [ES] dropped to >1000-folds). Specificity of exactin to 
macromolecular complexes (activators as well as substrates) was also determined. 
Compared to intrinsic tenase complex and RVV-X (exactin non-competitively 
inhibited FX activation with an affinity of ~ 2 µM), exactin exhibited nanomolar 
affinity to extrinsic tenase complex. Exactin was also found to be highly specific in 
inhibiting FX activation (>1000-folds) when compared to FIX, though both FX and 
FIX served as macromolecular substrates for the extrinsic tenase complex. Thus 
exactin specifically inhibited FX activation by extrinsic tenase complex and hence the 
name Extrinsic activation inhibitor/Exactin. Based on the sequence alignment, we 
found that exactin is identical to short neurotoxins. Inorder to study the usefulness in 
anticoagulant therapy, the neurotoxic effects of exactin was evaluated in in vivo and 
ex vivo experiments. Exactin was found to be a weak, reversible postsynaptic 
neurotoxin. Crystallization of exactin was also undertaken. Though diffracting quality 
crystals were obtained at high protein concentration (100 mg/ml), attempts to solve 
the structure were unsuccessful due to crystal twining. Currently efforts are being 
made to get good quality untwined crystals using various other crystallization 
conditions.  
Overall, we have functionally characterized a novel anticoagulant 3Ftx targeting the 
extrinsic activation complex. This is the first report of a three-finger toxin exhibiting a 






5.2. Future prospectives 
Though this thesis has addressed the purification and characterization of a novel 
anticoagulant protein exactin, further work needs to be carried out to better 
understand its binding site. This can not only help in structure-function studies but 
also improve our basic knowledge regarding exogenous factors targeting the 
coagulation cascade, specifically the extrinsic activation complex. Some of these 
answers can help in designing lead therapeutic molecules for future anticoagulation 
therapies. 
5.2.1. Co-crystallization of exactin with FX 
To understand the binding site of exactin on FX, co-crystallization studies will be 
carried out. FXa structure in complex with many exogenous factors is well studied 
(Murakami et al., 2007). For crystallization studies, the human FX will be subjected 
to a limited chymotryptic cleavage to remove the Gla domain as previous works 
revealed that presence of Gla domain might interfere with crystallization purpose 
(Morita et al., 1986). Though we crystallized exactin at very high concentrations (100 
mg/ml), the crystals obtained showed twining. Thus co-crystallization might also help 
to get better diffracting crystals of the complex.  
5.2.2. Biophysical studies with exactin 
The thermodynamics of binding of exactin to individual chains of FVIIa can be 
studied using biophysical techniques like ITC (isothermal titration calorimetry). The 
FVIIa heavy and light chain can be prepared through partial reduction using β-
mercaptoethanol and separation on an ion-exchange column (Kazama et al., 1993). 
The interaction studies will not only help to understand the binding site but will also 




5.2.3. Structure-function studies with exactin 
Determining the binding site of exactin on the extrinsic activation complex can help 
in delineating the functional site in exactin. This can be achieved through chemically 
modifying exactin and then examining its anticoagulant activity. The loop I-III of 
exactin harbours various basic and hydrophobic residues that can be subsjected for 
chemical modifications (Kini and Evans, 1989; Menez et al., 1990). Once the 
functional site (residues responsible for anticoagulant activity) is determined, short 
anticoagulant peptides can then be designed. The novelty of exactin lies in its dual 
role of anticoagulation and neurotoxicity. We thus predict these dual functional sites 
to present on different regions of exactin (Kini, 2002). Hence determining the 
anticoagulant site on exactin is important for designing lead molecules for future 
anticoagulation therapy. 
5.2.4. Characterization of other anticoagulants 
Though we have partially characterized other anticoagulants (with mass 7279 Da, 
mass 7438 Da and peak 10), it is important to understand their mechanism of action 
since these anticoagulants like exactin also inhibit FX activation by extrinsic tenase 
complex. Partial sequencing of these anticoagulants has shown the difference in 
sequence when compared to exactin. Thus structure-function studies  will not only 
explain how  these distinct anticoagulants recognize the extrinsic activation complex 
but also will help in identifying novel exosites in the complex, binding to which can 
exhibit anticoagulant activity. The knowledge thus gained can be used for designing 
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